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1. INTRODUCTION 
 Societal pressures to reduce healthcare costs, coupled with the pharmaceutical 
industries need to maintain its economic incentive to develop new drugs, have 
required that the industry increase speed to market and reduce the number of failures 
and overall cost of new drug development. This need has made it imperative for the 
industry to use efficient, systematic approaches to both drug discovery and 
formulation design. 
Oral drug delivery known for decades is the most widely utilized routes for 
administration among all routes that have been explored for systemic delivery of drug 
via various pharmaceutical products of different dosage forms. Popularity of the route 
may be ease of administration as well as traditional belief that by oral administration 
the drug is well absorbed like food stuff ingested daily. Sustained release (SR) or 
Controlled release (CR) pharmaceutical products have over the past decade gradually 
gained medical acceptance and popularity since, their introduction into the market has 
received regulatory approval for marketing and their pharmaceutical superiority and 
clinical benefits over immediate release pharmaceutical products have been 
increasingly recognized. Sustained release oral dosage forms have brought new lease 
of life into drugs that have lost market potential due to requirement of frequent 
dosing, dose related toxic effects and gastro intestinal disturbance. 
1.1 SUSTAINED RELEASE DELIVERY SYSTEM.1, 2 
The term ‘Sustained Release’ is known to have existed in the medical and 
pharmaceutical literature for many decades. Sustained release has been constantly 
used to retard the release of therapeutic agent such that its appearance in the 
circulation is steadily maintained and its plasma profile is prolonged. The onset of its 
pharmacological action is often delayed and duration of therapeutic action is 
sustained. 
In the recent years sustained release (SR) dosage forms continue to draw 
attention in the research for improved patient compliance and decreased incidence of 
adverse drug reactions. Sustained release, sustained action, prolonged action and 
extended action are  the terms used to identify drug delivery system that are designed 
to achieve a prolong therapeutic effect by continuously releasing medication over an 
extended period of time after administration of a single dose. Sustained release 
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technology is relatively new field and as a consequence, research in this field has been 
extremely fertile and has produced many discoveries. New and more sophisticated 
controlled release/sustained release delivery system are constantly being developed 
and tested.  
I] OBJECTIVES OF SUSTAINED RELEASE DRUG DELIVERY SYSTEMS.3 
In general the goal of sustained release dosage form is to maintain therapeutic 
blood or tissue level of the drug for extended period of time. This is generally 
accomplished by attempting to obtain “zero order” release from the dosage form. Zero 
order release constitutes drug release from the dosage form which is independent of 
the amount of drug in the delivery system. Sustained release systems generally do not 
attain this type of release and usually try to mimic zero order release by providing 
drug in slow “first order” fashion (i.e. concentration dependent). Thus sustained 
release dosage form is dependent. The sustained release dosage form consists of two 
parts:-  
[1] An immediately available dose to establish the blood level quickly in an 
amount sufficient to produce the desired Pharmacological response i.e.  
(Loading dose).  
[2] The remaining amount of total dose (maintenance dose) is then gradually 
released to maintain constant blood level of the drug. 
 
FIGURE: 1 
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B] CLASSIFICATION OF SUSTAINED RELEASE FORMULATIONS.4, 5 
 The sustained release dosage forms are categorized on the basis of structural and 
physical appearance such as single unit dosage form, multiple unit dosage form and 
mucoadhesive delivery systems. 
II) SINGLE UNIT DOSAGE FORMS:- 
 This refers to diffusion controlled systems where the drug is uniformly 
distributed (dissolved/dispersed) throughout the solid matrix or encapsulated by the 
polymer blend. This system can be classified as follows. 
A] Complex reservoir system or multilayered system or coated tablets:- 
 The core material which usually, the drug alone or blended with hydrophilic or 
hydrophobic inert material, is compressed into tablets, which is then coated with a 
hydrophobic or semi permeable film of polymer or a mixture of both. The release is 
controlled by the number of barriers. 
B] Osmotic Devices:- 
 The device is fabricated from a tablet that contains water soluble osmotically 
active drug, or that is blended with osmotically active diluents, by coating the tablet 
with semi permeable membrane barrier. Since barrier is permeable only to water, 
initial penetration of water dissolves the outer part of the core resulting in the 
development of osmotic pressure difference across the membrane. The device then 
delivers a volume of saturated solution equal to the volume of water uptake through 
membrane. 
C] Monolithic Devices:- 
 If the release rate is controlled or sustained by incorporating hydrophobic 
fillers within the matrix then the system is called monolithic device, where diffusion 
of drug through the matrix is rate limiting step. 
a) Floating tablets or capsules:- 
 These are designed to retain the drug in the stomach for extended period of 
time, by making the tablet to float in gastric juice at the stomach. This approach is 
suitable to the drugs which are liable to either degradation or poorly absorbed in distal 
part of GI tract. 
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b) Hydrophobic/swellable tablets:- 
Opium alkaloid such as morphine salts homogenized with a fatty acid or its salt and 
any ethylene vinyl acetate copolymer (hydrophobic filler) and then compressed into 
tablets was reported to give sustained release pattern of the drug during invitro 
studies. 
c)Semisolid matrix:- 
  Here drug is incorporated in an oily “semisolid” hydrophobic carrier (hydrogenated   
castor oil), and finally mass is usually filled into a gelatin capsule to repair dosage 
form. 
III) MULTIPLE UNIT DOSAGE FORMS:-  
      It represents a combination of the dosage form, the source of which may either 
be homogeneous or heterogeneous. It offers the advantage of combining two or more 
drugs, in a single dosage form where the patient requires combination therapy. 
Another advantage is to release one of the parts of the same can be sustained release. 
These are also useful where drug excipient and drug interactions are inevitable in a 
single unit dosage form. The various forms which are available are: 
A] Microgranules/spheroids:- 
 Drugs wet granulated alone or incorporated into inert granules, and then 
coated to control the release pattern. 
B] Beads:- 
Beads are prepared from various polymers and other inert materials that have 
been used as carrier to deliver the water soluble drugs orally in the form of sustained 
release preparation. 
C] Pellets:- 
 Pellets are prepared by coating inert drug pellets with film forming polymers. 
The drug release depends upon coating composition of polymers and amount of 
coating.  
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D] Microcapsules:-  
      Microcapsules are prepared by applying relatively thin coating to small 
particles of solids, droplet of liquid and dispersions. Its uniqueness lies in smallness of 
particles and their use and adaptation to a wide variety of dosage forms. 
IV) MUCOADHESIVE DELIVERY SYSTEM. 
It utilizes principle of bio-adhesion for optimum delivery of the drug from the 
device. Bio-adhesion is defined as the occurrence in which one biological substance is 
adhered to another substance which may either be biological or non biological origin. 
If the substrate is mucosal membrane, the phenomenon is known as "muco-adhesion". 
Mucoadhesive system is suitable to increase the contact time of drug with absorbing 
membrane and localization of delivery of drug at targeted sites. 
V) CHARACTERISTICS OF DRUGS UNSUITABLE FOR ORAL 
SUSTAINED RELEASE FORMS:-6 
1. Short biologic half-lives (< 1h), Long biologic half-lives (>12 h). 
2. Not effectively absorbed in the lower intestine. 
3.  Large doses required (>1g). 
4. Cumulative action and undesirable side effects; drugs with low therapeutic 
indices. 
5. Precise dosage is required to individual in case of anticoagulants, cardiac 
glycosides. 
 
VI) DRAWBACKS OF CONVENTIONAL DOSAGE FORMS:-7 
1. Poor patient compliance, increased chances of missing the dose of a drug with 
short half-life for which frequent administration is necessary.  
2. The unavoidable fluctuations of drug concentration may lead to under 
medication or over medication.  
3. A typical peak-valley plasma concentration-time profile is obtained which 
makes attainment of steady-state condition difficult.  
4. The fluctuations in drug levels may lead to precipitation of adverse effects 
especially of a drug with small Therapeutic Index (TI) whenever over 
medication occur.  
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VII) POTENTIAL ADVANTAGES AND DISADVANTAGES OF 
SUSTAINED RELEASE DOSAGE FORMS:-4, 6, 8 
a) ADVANTAGES:- 
(i) Therapeutic advantage:- 
               Reduction in drug plasma level fluctuation; maintain a steady plasma level 
of the drug over a prolonged time period, ideally simulating an intravenous infusion 
of a drug. 
(ii) Reduction in adverse side effects:- 
  Drug plasma levels are maintained within a narrow window with no sharp 
peaks and with AUC of plasma concentration versus time curve comparable with total 
AUC from multiple dosing with immediate release dosage forms. 
(iii) Patient comfort and compliance:- 
  Oral drug delivery is the most common and convenient for patients, and a 
reduction in dosing frequency enhances compliance. 
(iv) Reduction in healthcare cost:- 
              The total cost of therapy of the sustained release product could be 
comparable or lower than the immediate release product. With reduction in side 
effects, the overall expense in disease management also would be reduced. 
(v) Avoid night time dosing:- 
  It is also good for patients to avoid the dosing at night time. 
b)DISADVANTAGES: 
(i) Dose dumping. 
  Dose dumping is a phenomenon where by relatively large quantities of drug 
in a sustained release formulation is rapidly released, introducing potential toxic 
quantities of the drug into the systemic circulation. Dose dumping can lead to 
fatalities in case of potent drug, which have a narrow therapeutic index e.g. 
Phenobarbital. 
(ii) Less flexibility in accurate dose adjustment. 
  In conventional dosage forms, dose adjustments are much simpler e.g. tablet 
can be divided into two fractions. But sustained release property may get lost, if 
dosage form is fractured. 
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(iii) Poor In vitro – In vivo correlation. 
In sustained release dosage form, the rate of drug release is deliberately 
reduced to a large region of gastrointestinal tract. Hence it is called as ‘Absorption 
window’ which becomes important and may give rise to unsatisfactory drug 
absorption invivo despite excellent invitro release characteristics. 
(iv) Patient variation. 
 The time period required for absorption of drug release from the dosage form 
may vary among individuals. Co-administration of other drugs, presence or absence 
of food and residence time in gastrointestinal tract is different among patients. This 
also gives rise to variation in clinical response among the patient.  
 
1.2 FACTORS INFLUENCING ORAL RELEASE DOSAGE FORMS.9 
A] PHYSICO-CHEMICAL PROPERTIES. 
i) MOLECULAR SIZE AND DIFFUSIVITY. 
The ability of a drug to diffuse in polymers, its so-called diffusivity (diffusion 
coefficient D), is a function of its molecular size (or molecular weight).  For most 
polymers, it is possible to relate log D empirically to some function of molecular size 
as  
Log D = -sv log u + kv = -sM log M + km 
Where, v is molecular volume, M is molecular weight, sv, sM, kV and km are 
constants.  The value of D thus is related to the size and shape of the cavities as well 
as size and shape of drugs. The diffusion   co-efficient of intermediate molecular 
weight drug i.e;100 to 400 Daltons, through flexible polymer ranges from 10-6 to 10-9 
cm2 /sec. For drugs having molecular weight > 500 Dalton the diffusion co-efficient 
in many polymer are very less i.e.; less than 10-12 cm2 / sec. Drugs with large 
molecular size are poor candidates for oral SR drug delivery system because it is very 
difficult to control release rate of medicament from dosage form e.g. proteins and 
peptides. 
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ii) AQUEOUS SOLUBILITY. 
As the drug must be in solution form before absorption, drugs having low 
aqueous solubility usually suffer oral bioavailability problem due to limited GI transit 
time of undissolved drug and limited solubility at absorption site. So these types of 
drugs are undesirable. Drugs having extreme aqueous solubility are undesirable for 
SR because, it is too difficult to control release of drug from the dosage form. 
Physiological pH dependent solubility i.e. variation in solubility at different GI pH 
values are undesirable (e.g. Aspirin, which is less soluble in stomach, but more 
soluble in intestine) as it will yield variation in dissolution rate. A drug with good 
aqueous solubility pH independent solubility is desirable for oral new drug delivery 
systems. The Bio-pharmaceutical Classification (BCS) System allows estimation of 
likely contribution of three major factors solubility, dissolution and intestinal 
permeability which affect the oral drug absorption. 
Classification of drugs according to Bio-pharmaceutical classification system. 
Class I:  High solubility-High permeability 
Class II:  Low solubility High permeability 
Class III: High solubility Low permeability 
Class IV:  Low solubility-Low permeability 
High solubility: Largest dose dissolves in 250 ml of water over a PH range 1-8 
High permeability: Extent of absorption is > 90% 
Class III and Class IV drugs are poor candidates for SR/CR dosage forms.  
 
Examples of drugs which are poor candidates for SR/CR release systems. 
 
1. Drugs which are limited in the absorption by their dissolution rates are 
digoxin, warfarin, griseofulvin, and salicylamide. 
2. Drugs poorly soluble in the intestine (acid soluble basic drugs): diazepam, 
diltiazem, cinnarizine, chlordiazepoxide, and chlorpheniramine. 
3. Drugs having lower solubility in stomach: furosemide. 
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iii) IONIZATION CONSTANT(pKa).  
As we know only unionized drugs are absorbed and permeation of ionized 
drug is negligible, since its rate of absorption is 3 to 4 time less than that of the 
unionized drug. The PKa range for acidic drug where ionization is pH sensitive is 
around 3.0 - 7.5 and pKa range for basic drug whose ionization is pH sensitive is 
around 7.0 – 11.0 are ideal for optimum positive absorption. Drugs shall be non-
ionized at the site to an extent 0.1 – 5%. Drugs existing largely in ionized form are 
poor candidates for oral SR drug delivery system e.g. Hexamethonium.  
iv) PARTITION COEFFICIENT.  
As biological membranes are lipophilic in nature through which the drug has 
to pass through, the partition co-efficient of drug influences the bioavailability. Drugs 
having lower partition co-efficient values less than the optimum activity are 
undesirable for oral SR drug delivery system, as they have very less lipid solubility 
and the drugs will be localized at the first aqueous phase when they come in contact 
viz, Barbituric acid. Drugs having higher partition co-efficient values greater than the 
optimum activity are undesirable for oral SR drug delivery system because more lipid 
soluble drugs will not partition out of the lipid membrane once they get in to the 
membrane. The value of partition co-efficient at which optimum activity is observed 
is approximately 1000 : 1 in 1-octanol / water system. 
A major criterion in evaluation of the ability of a drug to penetrate these lipid 
membranes (i.e., its membrane permeability) in its apparent oil/water partition 
coefficient, defined as  
                                               K = CO/CW  -------- (1) 
Where CO is the equilibrium concentration of all forms of the drug in an 
organic phase at equilibrium, and CW is the equilibrium concentration of all forms in 
an aqueous phase. In general, drugs with extremely large values of K are very oil-
soluble and will partition into membranes quite readily.  The relationship between 
tissue permeation and partition coefficient for the drug generally is defined by the 
Hansch correlation, which describes a parabolic relationship between the logarithm 
of the activity of a drug or its ability to be absorbed and the logarithm of its partition 
coefficient. 
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v) STABILITY. 
 One important factor for the loss of drug is through acid hydrolysis and/or 
metabolism in the GIT when administered orally.  It is possible to improve 
significantly the relative bioavailability of a drug that is unstable in GIT by placing it 
in a slowly available controlled release form, for those drugs that are unstable in the 
stomach the most appropriate controlling unit would be one that releases its content 
only in the intestine. The release in the case for those drugs that are unstable in the 
environment of the intestine, the most appropriate controlling unit in this case would 
be one that releases its contents, only in the stomach. So, drugs with significant 
stability problems in any particular area of the GI tract are less suitable for 
formulation into controlled release systems that deliver the contents uniformly over 
the length of GI tract.  
Acid unstable drugs (stomach). 
  Examples: Rabeprazole, pantoprazole, omeprazole, lansoprazole, esomeprazole, 
rifamipicin, mesalazine, erythromycin, riboflavin 
Alkaline unstable drugs (drugs that are unstable in intestine and colon): 
      Ex: Captopril, ranitidine. 
vi) DOSE SIZE. 
If a product has dose size > 0.5g it is a poor candidate for oral SR drug 
delivery system, because an increase in bulk of the drug, leads to increase the volume 
of the product. 
1.2.2 BIOLOGICAL FACTORS. 10 
i) ABSORPTION 
The rate, extent and uniformity of absorption of a drug are important factors when 
considering its formulation into a sustained release system. Since the rate limiting step 
in drug delivery from a sustained release system is its release from a dosage form, 
rather than absorption. A rapid rate of absorption of drug relative to its release is 
essential if the ‘system is to be successful’.  
INTRODUCTION 
 
DEPT OF PHARMACEUTICS, KM COLLEGE OF PHARMACY. Page 11 
 
1. Drugs absorbed by active transport system are unsuitable for 
sustained/controlled drug delivery system: methotrexate, enalapril, riboflavin, 
pyridoxine, 5-fluorouracil, 5-bromo uracil, nicotinamide, fexofenadine, 
methyl-dopa. 
2. Drugs absorbed through amino acid transporters in the intestine: 
cephalosporins, gabapentine, baclofen, methyl-dopa, levo-dopa. 
3. Drugs transported through Oligo-peptide transporters, captopril, lisinopril, 
cephalexine, cefadroxil, cefixime. 
4. Drugs required to exert a local therapeutic action in the stomach are unsuitable 
for sustained /controlled drug delivery.  
           Ex: misoprostol, 5-fluorouracil, antacids, anti-helicobacter pylori agents. 
b) ABSORPTION WINDOW. 
Some drugs display region specific absorption which is related to differential 
drug solubility and stability in different regions of GIT, as a result of changes in 
environmental pH, degradation by enzymes, etc. These drugs show absorption 
window, which signifies the region of G.I tract where absorption primarily occurs.  
Drugs release from sustained/controlled release systems, after absorption window has 
been crossed with little/no negligible absorption. Hence absorption window can limit 
the bioavailability of orally administered compounds and can be a major obstacle to 
the development of sustained/controlled release drugs. 
 Examples of Drugs exhibiting the site specific absorption in stomach or upper 
parts of small intestine (absorption window) are: 
   Acyclovir, captopril, metformin, gabapentin, atenolol, furosemide, ranitidine, 
levo-dopa, sotalol, salbutamol, riboflavin, sulfonamides, loratadine, cephalosporines, 
tetracyclines, verapamil, thiamine, sulpiride, baclofen, nimesulide, cyclosporine, 
quinolines. 
c) DISTRIBUTION.  
The distribution of a drug into vascular and extra vascular spaces in the body 
is an important factor in its overall elimination kinetics. Two parameters that are used 
to describe the distribution characteristics of a drug are its apparent volume of 
distribution is the ratio of drug concentration in the tissue to that in plasma at the 
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steady state called therapeutic ratio. The magnitude of the apparent volume of 
distribution can be used as a guide for addition studies and as a predictor for a drug 
dosing regimen and hence the need to employ a sustained release system. 
d )METABOLISM. 
 Drugs with extensive metabolism are not suitable for SR drug delivery 
systems. A drug capable of inducing metabolism, inhibiting metabolism, metabolized 
at the site of absorption or first-pass effect is poor candidate for SR drug delivery 
system, since it will be difficult to maintain constant blood level i.e. levodopa, 
nitroglycerine. Fluctuating drug blood levels due to intestinal metabolism upon oral 
dosing:  
 Examples: Salicylamide  isoproterenol, clonazepam, hydralazine and 
levodopa.                            
Fluctuating drug blood levels due to first pass hepatic metabolism upon oral dosing: 
Examples: Nortriptyline, phenacetin, morphine, propranolol. 
Fluctuating blood levels due to enzyme induction are poor candidates for 
Sustained/controlled Release dosage forms: 
Examples: Griseofulvin, phenytoin, primidone, barbiturates, rifampicin. 
Fluctuating blood levels due to enzyme inhibition are poor candidates for 
Sustained/Controlled Release dosage forms: 
Examples: Isoniazid, cimetidine, amiodarone, erythromycin, fluconazole, 
ketoconazole, mao –inhibitors, para - aminosalicyclic acid, allopurinol, coumarins. 
e) HALF LIFE.  
 A drug having biological half-life between 2 to 8 hours is best suited for oral 
SR drug delivery system. If the biological half-life of a drug is < 2 h the system will 
require unacceptably large dose, whereas the biological half-life is > 8 h formulation 
of such drug into oral SR drug delivery system is unnecessary.  
f) DRUG -PROTEIN BINDING. 
 The pharmacological response of drug depends on unbound drug 
concentration rather than total drug concentration and all drugs bound to some extent 
to plasma and or tissue proteins. Protein binding of drug plays a significant role in its 
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therapeutic effect regardless the type of dosage form as extensive binding to plasma 
increases the biological half-life and thus sometimes SR drug delivery system is not 
required for this type of drugs.  
      The role of protein binding as a factor in formulation of S.R/C.R dosage forms 
can be explained by considering angiotensin-II antagonist class of drugs. The drugs of 
this class are highly protein bound (>99%). Tasosartan is a long acting AT-II receptor 
blocker with a protein binding of 99.8%, while it’s long acting active metabolite; 
Enoltasosartan has a protein binding 99.9%. 
g) DISEASE STATE. 
Even, in some cases are considered before the designing of an oral sustained 
delivery. This can be explained by the following classical examples. Aspirin is a drug 
of choice for rheumatic arthritis, and it is not a suitable candidate for sustained release 
dosage form. Still an aspirin sustained release dosage form could be advantageous to 
maintain therapeutic concentrations, particularly throughout the night, thus alleviating 
morning stiffness. 
h) THERAPEUTIC INDEX. 
It is most widely used to measure the margin of safety of a drug.                            
                                              TI = TD50 /ED50 
The longer the value of Therapeutic index (TI), the safer the drug. Drugs with 
very small value of Therapeutic index are poor candidates for formulation into 
sustained release products. A drug is considered to be safe if its Therapeutic value is 
greater than 10. 
i) DOSES FORM INDEX.  
It is the ratio of Cssmax to Cssmin. It is the goal of oral SR drug delivery system 
is to improve therapy by reducing the doses form index while monitoring the plasma 
drug level within the therapeutic window. So ideally the doses form index should be 
as close as to one. 
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1.3 SUSTAINED RELEASE MATRIX SYSTEMS.  
A matrix tablet is the simplest and the most cost-effective method to fabricate 
an sustained-release dosage form. The majority of commercially available matrix 
formulations are in the form of tablets and their manufacture is similar to 
conventional tablet formulations consisting of granulation, blending, compression and 
coating steps. In its simplest form, a typical SR matrix formulation consists of a drug, 
release retardant polymer (hydrophilic or hydrophobic or both), one or more exipients 
(as filler or binder), flow aid (glidant) and a lubricant. Other functional ingredients 
such as buffering agents, stabilizers, solubilizers and surfactants may also be included 
to improve or optimize the release and/or stability performance of the formulation 
system. 
These releases the drug by both dissolution controlled as well as diffusion 
controlled mechanisms. To control the release of the drugs, which are having different 
solubility properties, the drug is dispersed in swellable hydrophilic substances, an 
insoluble matrix of rigid nonswellable hydrophobic materials or plastic materials. 
1.3.1 CLASSIFICATION OF MATRIX TABLETS.11, 12 
A] ON THE BASIS OF RETARDANT MATERIAL USED. 
(i) Hydrophobic Matrices (Plastic matrices).  
In this method of obtaining sustained release from an oral dosage form, drug is 
mixed with an inert or hydrophobic polymer and then compressed into a tablet. 
Sustained release is produced due to the fact that the dissolving drug has diffused 
through a network of channels that exist between compacted polymer particles.   
Examples of materials that have been used as inert or hydrophobic matrices include 
polyethylene, polyvinyl chloride, ethyl cellulose and acrylate polymers and their 
copolymers.  
The rate-controlling step in these formulations is liquid penetration into the 
matrix. The possible mechanism of release of drug in such type of tablets is diffusion. 
Such types of matrix tablets become inert in the presence of water and gastrointestinal 
fluid. 
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(ii) Lipid Matrices. 
These matrices prepared by the lipid waxes and related materials. Drug release 
from such matrices occurs through both pore diffusion and erosion. Release 
characteristics are therefore more sensitive to digestive fluid composition than to 
totally insoluble polymer matrix. Carnauba wax in combination with stearyl alcohol 
or stearic acid has been utilized for retardant base for many sustained release 
formulations.  
(iii) Hydrophilic Matrices. 
A matrix is defined as well mixed composite of one or more drugs with a 
gelling agent (hydrophilic polymer). These systems are called swellable controlled 
release systems. 
Hydrophilic matrices are the most commonly used oral sustained-release 
systems because of their ability to provide desired release profiles for a wide range of 
drugs, robust formulation, cost-effective manufacture, and broad regulatory 
acceptance of the polymers. The polymers used in the preparation of hydrophilic 
matrices are divided into three broad groups, 
• Cellulose derivatives: methylcellulose 400 and 4000 cps, HPMC-25, 100, 
4000 and 15000 cps and Sodium CMC.  
• Noncellulose natural or semisynthetic polymers: agar-agar, Xanthan gum, 
carob gum, alginates, molasses, polysaccharides of mannose and galactose, 
chitosan and modified starches.  
• Polymers of acrylic acid, corbopol 934, the most used variety. 
(iv) Biodegradable Matrices.  
These consist of the polymers which comprised of monomers linked to one 
another through functional groups and have unstable linkage in the backbone. They 
are biologically degraded or eroded by enzymes generated by surrounding living cells 
or by nonenzymatic process into olegomers and monomers that can be metabolized or 
excreted. 
Examples are natural polymers such as proteins and polysaccharides; modified natural 
polymers synthetic polymers such as aliphatic poly (esters) and poly anhydrides. 
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(v) Mineral Matrices. 
These consist of polymers which are obtained from various species of 
seaweeds. Example is Alginic acid which is a hydrophilic carbohydrate obtained from 
species of brown seaweeds (Phaephyceae) by the use of dilute alkali.   
B] ON THE BASIS OF POROSITY OF MATRIX. 
Matrix system can also be classified according to their porosity and 
consequently, macroporous, microporous and non-porous systems can be identified. 
(i) Macroporous Systems.  
In such systems the diffusion of drug occurs through pores of matrix, which 
are of size range 0.1 to 1µm. This pore size is larger than diffusant molecule size 
(ii) Microporous System. 
           Diffusion in this type of system occurs essentially through pores. For 
microporous systems, pore size ranges between 50 – 200 A°, which is slightly larger 
than diffusant molecules size. 
(iii) Non-porous System. 
Non-porous systems have no pores and the molecules diffuse through the 
network meshes. In this case, only the polymeric phase exists and no pore phase is 
present. 
C] ADVANTAGES OF MATRIX TABLETS. 
• Easy to manufacture  
• Versatile, effective and low cost  
• It can be made to release high molecular weight compounds  
D] DISADVANTAGES OF THE MATRIX SYSTEMS. 
• The remaining matrix must be removed after the drug has been released.  
• The drug release rates vary with the square root of time.  
• Release rate continuously diminishes due to an increase in diffusional 
resistance and/or a decrease in effective area at the diffusion front. However, a 
substantial sustained effect can be produced through the use of very slow 
release rates, which in many applications are indistinguishable from zero-
order.  
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E] POLYMERS USED IN MATRIX TABLETS. 13 
The use of polymers in controlling the release of drugs has become important 
in the formulation of sustained release dosage form. Water soluble polymers may be 
used to increase the dissolution rates of poorly soluble drugs. Hydrogels provide the 
basis for implantation, transdermal and oral controlled release systems.  
a) HYDROGELS. 
• Polyhydroxyethylemethylacrylate (PHEMA)  
• Cross-linked polyvinyl alcohol (PVA)  
• Cross-linked polyvinyl pyrolidone (PVP)  
• Polyethylene oxide (PEO)  
• Polyacrylamide (PA)  
b) SOLUBLE POLYMERS. 
• Polyethylene glycol (PEG)  
• Polyvinyl alcohol (PVA)  
• Polyvinyl pyrrolidone (PVP)  
c) SOLUBLE POLYMERS. 
• Polyethylene glycol (PEG)  
• Polyvinyl alcohol (PVA)  
• Polyvinyl pyrrolidone (PVP)  
• Hydroxypropyl methyl cellulose (HPMC)  
d) BIODEGRADABLE POLYMERS.                  
• Polylactic acid (PLA)  
• Polyglycolic acid (PGA)  
• Polycaprolactone (PCL)  
e) NONBIODEGRADABLE POLYMERS. 
• Polyethylene vinyl acetate (PVA)  
• Polydimethylsiloxane (PDS)  
• Polyvinylchloride (PVC)  
• Cellulose acetate (CA)  
• Ethyl cellulose (EC) 
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f) MUCOADHESIVE POLYMERS. 
• Polycarbophil 
• Sodium carboxymethyl cellulose  
• Polyacrylic acid  
• Methyl cellulose  
• Pectin  
g) NATURAL GUMS.                     
• Xanthan gum  
• Guar gum  
• Karaya gum 
1.4 MECHANISM OF HYDROPHILIC MATRIX TABLETS.14, 15 
                 The mechanism of drug release from hydrophilic matrix tablets after ingestion 
is complex but it is based on diffusion of the drug through, and erosion of the outer 
hydrated polymer on the surface of the matrix. Typically, when the matrix tablet is 
exposed to an aqueous solution or gastrointestinal fluids, the surface of the tablet is 
wetted and the polymer hydrates to form a gelly-like structure around the matrix, 
which is referred to as the “gel layer”. This process is also termed as the glassy to 
rubbery state transition of the (surface layer) polymer. This leads to relaxation and 
swelling of the matrix which also contributes to the mechanism of drug release. 
 The core of the tablet remains essentially dry at this stage. In the case of a 
highly soluble drug, this phenomenon may lead to an initial burst release due to the 
presence of the drug on the surface of the matrix tablet. The gel layer (rubbery state) 
grows with time as more water penetrates into the core of the matrix, thereby 
increasing the thickness of the gel layer and providing a diffusion barrier to drug 
release. Simultaneously, as the outer layer becomes fully hydrated, the polymer chains 
become completely relaxed and can no longer maintain the integrity of the gel layer, 
thereby leading to disentanglement and erosion of the surface of the matrix. Water 
continues to penetrate towards the core of the tablet, through the gel layer, until it has 
been completely eroded.  
Soluble drugs can be released by a combination of diffusion and erosion 
mechanisms whereas erosion is the predominant mechanism for insoluble drugs. For 
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successful sustained release of drugs, it is essential that polymer hydration and surface 
gel layer formation are quick so as to prevent immediate tablet disintegration and 
premature drug release. For this reason, polymers for hydrophilic matrices are usually 
supplied in small particle size to ensure rapid hydration and consistent formation of 
the gel layer on the surface of the tablet. A large number of mathematical models have 
been developed to drug release profiles from matrices. The simple and more widely 
used model is the one derived by Korsemeyer et al. and is as follows: 
Mt / Mα = k t n----------------- (1) 
 Where, 
 Mt / Ma is the fraction of drug release 
 ‘k’ is the diffusion rate constant 
 ‘t' is the release time 
 ‘n’ is the release exponent indicative of the mechanism of drug release. 
The equation was modified by Ford et al. to account for any lag time or initial 
burst release of the drug 
Mt / Ma = k (t – 1) n ------------------ (2)                    
  Where,  l = lag time.  
            It is clear from both equations that when the exponent n takes a value of 1.0, 
the drug release rate is independent of time. This case corresponds to zero-order 
release kinetics (also termed as case II transport). Here, the polymer relaxation and 
erosion are the rate-controlling steps. When n = 0.5, Fickian diffusion is the rate-
controlling step (case I transport). Values of n between 0.5 and 1 indicate the 
contribution of both the diffusion process as well as polymer relaxation in controlling 
the release kinetics (non-Fickian, anomalous or first-order release). It should be noted 
that the two extreme values of n = 0.5 and 1 are only valid for slab geometry.For 
cylindrical tablets, these values range from 0.45 <n < 0.89 for Fickian, anomalous or 
case II transport respectively. 
  In general, two major factors control the drug release from swelling controlled 
matrix system. They include 
1. The rate of aqueous medium infiltration into the matrix, followed by a relaxation 
process (hydration, gelatin or swelling) 
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 2. The rate of matrix erosion
                As a result of these simultaneous processes, two front are evident, a 
swelling front, where the polymer get hydrated, and an eroding front. The distance 
between these two fronts are called diffusi
              Diffusion layer thickness depends on the selective rate at which the swelling 
and eroding fronts move in relation to each other. If the polymer gets slowly, solvent 
can penetrate deep into the glassy matrix thus dissolvin
thickness and it stability are council in controlling drug release. 
               Swelling of HPMC matrix tablet was higher for
They attributed this to the large hydrod
weight chain when hydrated. As the polymer chain becomes more hydrated and the 
gel becomes more dilute, the disentanglement concentration may be reached that is, 
the critical polymer concentration 
and detached from gelled matri
Matrix Dissolution control:
                In this system an alternative approach is to compress the drug with a slow 
dissolving carrier. Here the rate of drug release is controlled by the rate of 
of the dissolution fluid into the matrix, porosity, presence of hydrophobic additives 
and the wettability of system and surface of particle
 
 
 
 
                          
                             
 
Fig: 2 Matrix dissolution controlled drug delivery
 
 
INTRODUCTION
 
  
on layer thickness.  
g the drug; there
 
 a high molecular weight. 
ynamic volume occupied by hig
was below in which the polymer chain 
x. 
16,17 
 
 
 
Page 20 
fore gel layer 
h molecular 
disentangle 
penetration 
INTRODUCTION 
 
DEPT OF PHARMACEUTICS, KM COLLEGE OF PHARMACY. Page 21 
 
1.5  DRUGS SUITABLE FOR SUSTAINED RELEASE FORMULATIONS.18,19 
Not all drugs lend themselves to the formulation of a sustained release product. 
The important factors that are to be considered in the choices of a drug as a candidate 
of SR preparations are as follows. 
 a) Biological half-life  
Only drugs with short biological half lives (2-4 hours) make good candidates 
for SR systems, but a larger dose may be required to maintain high release rate. 
Conversely, drugs with long half-lives can be given at less frequent intervals 
and hence there is no advantage in formulating these drugs as sustained release 
formulations. 
The pharmaceutical effect of some drugs with short half-lives is sustained by 
various mechanisms. 
 The drug binds to the tissues. 
      Eg: Tissue-bound angiotensin convering enzyme(ACE) inhibitors. For these 
drugs, less frequent dosing is needed even though the drug is having a shorter half-
life.  
 The drugs have irreversible effects 
     Eg. The inhibition of platelet cycloxygenase by aspirin.  
 The relationship between response and plasma / blood concentration is relatively 
flat or if the dose given results in concentrations which are in the plasma region of 
the dose response relationship. 
     Eg: - Thiazides in hypertension.  
 The drug is metabolized to pharmacologically active metabolite (s) which are 
more slowly cleared than the parent drug. 
      Eg:- Quinapril, Trandolapril, Venlafaxine 
b) Therapeutic range 
Drugs that are highly potent such as cardiac glycosides should not be 
considered for SR preparations due to loss in flexibility in dosage regimen and 
potential sudden dose dumping. 
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c)  GI absorption 
Most SR formulations are dissolution controlled; release rate from the dosage 
from being the rate-limiting step. Once the drug is released, it is transferred from the 
intestinal lumen to the blood. Therefore efficient drug absorption from GIT is a 
prerequisite for oral controlled release dosage forms. 
d)  Stability to wide pH range, GI enzymes and flora 
For an orally administered drug, stability in the GI contents is necessary to 
ensure complete and reproducible drug input into the body, since drug will be exposed 
to luminal contents. Unlike conventional dosage forms, a SR formulation is exposed 
to the entire pH range and enzymes. In colonic absorption, stability to metabolizing 
effect of colonic bacteria is also required. 
e) First pass metabolism 
Hepatic metabolism may render a drug unsuitable for oral SR release. This is 
because systemic availability for such a drug is highly reduced when input rate is 
small. 
1.5.1 STABILITY OF THE SUSTAINED ACTION DOSAGE FORM DURING 
STORAGE.20 
For all the pharmaceutical dosage forms it is important to determine the 
stability of the dosage form. This will include storage at both normal and exaggerated 
temperature conditions with the necessary extrapolations to ensure the product will, 
over its designed shelf life, provide medication for absorption at the same rate as 
when originally formulated. The design of the format stability studies for the drug 
product should be based on knowledge of the behavior and properties of the drug 
substance and from stability studies on the drug substance. 
a)SELECTION OF BATCHES. 
 Data from stability studies should be provided on at least three concurrent 
batches of the drug product. The primary batches should be of the same formulation 
and packaged in a same type of package as proposed for marketing. The 
manufacturing process used for primary batches should simulate that, to be applied to 
production batches and should provide product of the same quality & making the 
same specification as that intended for marketing. Two of the three batches should be 
at least pilot-scale batches & the third one can be smaller. 
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b) SPECIFICATION. 
Specification, which is the list of tests, reference to analytical procedures and 
proposed acceptance criteria, including the concept of different acceptable criteria for 
release and shelf life specifications. 
 Stability studies should include testing of those attributes of the drug product 
that are susceptible to change during storage and likely to   influence quality, safety 
and efficiency. The testing should cover, as appropriate, the physical, chemical, 
biological and microbiological attributes, preservative content and functionality tests 
(e.g. for a dose delivery system). Analytical procedures should be fully validated and 
stability indicated. 
c) TESTING FREQUENCY. 
 For long-term studies, frequency of testing should be sufficient to establish the 
stability profile of the drug product. For a product with a proposed shelf life of at least 
12 months, the frequency of testing at the long term storage condition should 
minimum of 3 months over the first year, every 6 months over the second year and 
annually thereafter through the proposed shelf life.  
 At the accelerated storage condition, a minimum of three time points, 
including the initial and final time points (e.g. 0, 3, and 6 months), from a 6 month 
study is recommended. When testing at the immediate storage condition is called for 
as a result of significant change at the accelerated storage condition, a minimum of 
four time points, including the initial and final points (e.g. 0, 6, 9, and 12) from a 12 
month day is recommended. 
d) STORAGE CONDITIONS. 
 In general, a drug product should be evaluated under storage conditions that 
test its stability and if applicable, its sensitivity to moisture or potential for solvent 
loss. The long-term testing should cover a minimum of 12 months duration or at least 
three batches at the time of submission and should, be continued for a period of the 
sufficient time by covering the proposed shelf life. Long-term, accelerated and where 
appropriate, intermediate storage conditions for drug products are detailed in sections 
below.  
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                                Table 1. Storage Conditions for Stability Studies. 
Study Storage condition 
Minimum Time Period 
Covered by data at submission 
Long term  250C ± 20C/60% RH ± 5% RH 12 months 
Intermediate  300C±20C/60% RH ± 5% RH 6 months 
Accelerated  400C ± 20C/75% RH ± 5% RH 6 months 
  
When “significant change” occurs at any time during 6 months testing at the 
accelerated storage condition, additional testing at the immediate storage condition 
should be conducted and evaluated against significant change criteria.  
In general significant change for a drug product is defined as:  
1) A 5% change in assay from its initial value; or failure to meet the acceptance 
criteria for when using biological or immunological procedures. 
2) Any degradation products exceeding its acceptance criterion.  
3) Failure to meet the acceptance criterion for appearance, physical attributes, and 
functionality test. Eg: - Hardness, dose delivery per activation however, some 
changes in physical attributes may be expected under accelerated conditions and 
as appropriate for the dosage form.  
4) Failure to meet the acceptance criterion for pH.  
5) Failure to meet the acceptance criterion for dissolution for 12 dosage units.  
Storage conditions are maintained as stated in ICH guidelines. The 
globalization and increase in worldwide trade in recent has led to the need for 
international drug approvals and unification of regularly requirements & evaluation 
products. ICH has already a number of harmonized guidelines providing guidance on 
generation of data that would be acceptable in the European Union, Japan & USA. 
 When available long-term stability data on primary batches do not cover the 
proposed shelf life granted at the time of approval, a commitment should be made to 
continue the stability studies post approval in order to firmly establish the shelf life. 
The stability protocol used for studies on commitment batches should be the same as 
that for the primary batches.18 
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e) EVALUATION. 
 A systematic approach should be adopted in the presentation and evaluation 
of the stability information, which should include as appropriate, results from the 
physical, chemical, biological and microbiological tests, including particular attributes 
of the dosage form. The purpose of the stability study is based on the testing a 
minimum of three batches of drug product, a shelf life and label storage instructions 
applicable to all future batches of the drug product manufactured and packaged under 
similar circumstances. 
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2.1  LITERATURE REVIEW ON GLUCOSAMINE:- 
 Gabriel herrero-beamont et al (2007)., studied the effects of glucosamine 
sulfate (1500mg administered once daily) for osteoarthritis during a 6month course by 
oral route of administration. The findings of study was that glucosamine sulfate at the 
oral once-daily dosage of 1500mg is more effective than placebo in treating 
osteoarthritis. Although acetaminophen also had a higher responder rate compared with 
placebo.21 
 S.Persiani et al (2007)., investigated the synovial and plasma glucosamine 
concentration in osteoarthritis patients following oral administration of crystalline 
glucosamine sulphate at a therapeutic dose of 1500mg once-daily-dose for 14days. The 
glucosamine was bioavailable both systemically and at the site of action after oral 
administration of crystalline sulphate in osteoarthritis patients. Steady state of 
glucosamine concentration in plasma and synovial fluid were correlated and in line with 
those effective in selected invitro studies.22 
 Ali Aghazazeh-habashi et al (2002)., studied the single dose pharmacokinetics 
of glucosamine by various routes of administration of hydrochloride salts to rats and to 
locate the site of its first pass metabolism. Serial blood samples were collected and 
determined by using HPLC. They found out that orally administered glucosamine is 
rapidly absorbed, highly distributed, and effectively cleaned.23 
 E. Roda et al (2005)., studied the pharmacokinetic data on glucosamine, limiting 
the understanding of glucosamine sulfate mechanism of action in support of its treatment 
effects in osteoarthritis. Glucosamine is bioavailable after oral administration of 
crystalline glucosamine sulfate, persists in circulation and its pharmacokinetics support 
once-daily dosage. Steady state peak concentration at the therapeutic dose of 1500 mg 
was in line, with those found to be effective in selected invitro mechanistic studies. 
Glucosamine elimination half-life was only tentatively estimated to average 15 h.24 
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 M.Basak et al (2006)., studied the absorption of 2 different formulations of 
glucosamine sulfate in randomized, multi-dose, two ways, and crossover study. The 
novel timed release pellet filled Hard gelatin shell capsule (TimeOsamineTM) was 
compared with a power-filled hard gelatin shell. The timed release capsule was used in 
double dose of 1000 mg (2 x 500 mg) with an interval of 12 h whereas filled hard gelatin 
capsule was used in triple dose of 1500 mg (3 x 500 mg) with an interval of 8 h after 10 h 
pre-dose fasting. The concentration of glucosamine was measured after 24h. 
Pharmacokinetics properties including area under curve AUC, Cmax, Tmax were 
measured. After reduction in the dose by 33 % the AUC0-24 of TimeOsamineTM is 96.37% 
with respect to power-filled formulation AUC0-24 was compared.25  
 May M.Chou et al (2008)., examined the effects of chondroitin sulfate (CS) 
alone and CS plus glucosamine sulftate (GS) in a dietary bar formulation on 
inflammatory parameters of adjuvant-induced arthritis and on synthesis of interleukin-
1β(1L-1β) and matrix metalloprotease-9 (MMP-9).The combination of chondroitin 
sulfate and glucosamine sulfate in a dietary bar more so than chondroitin sulfate 
ameliorates parameters of rheumatoid arthritis.26 
 S.Sandhya et al (2007)., studied the effect of glucosamine and 
glycosamineglycans on matrix metalloproteinase (MMPs) in type II collagen induced 
experimental arthritis. As MMPs appear to play a key role in the degradation of cartilage 
matrix in the progression of arthritic disease, MMPs are considered as potential 
therapeutic targets. The oligosaccharides treated animals showed considerably lower 
MMP activity (particularly MMP9) compared with arthritic control. The chondroitin 
sulfate A (and the oligosaccharides derived from it) not only reduced the activity of 
MMPs, indicating that the production of MMPs is affected. The antiarthritic effect of 
chindroitin sulphate A involves down-regulation of MMPs, which are critically involved 
in progression of arthritic disease.27 
 Sheila laverty et al (2005)., studied the concentration of glucosamine 
hydrochloride in the synovial fluid and its pharmacokinetics in serum in a large animal 
model following dosing with glucosamine hydrochloride at clinically relevant doses. It 
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provides both high reproducibility and high recovery of standard glucosamine 
hydrochloride as its acetylated derivative over the concentration range of interest for 
analysis of biologic fluids. The apparent therapeutic benefit of dietary glucosamine on 
pain and joint space width in humans and animals maybe secondary to its effects on 
nonarticular tissues, such as the intestinal lining, liver, or kidney, since these maybe 
exposed to much high levels of glucosamine following ingestion.28 
 Chanda kulkarniet et al (2011)., compared the safety and efficacy of 
Glucosamine hydrochloride- sustained release (GLU-SR) with that of Glucosamine 
hydrochloride immediate release (GLU-IR) in patients with knee osteoarthritis (OA). It 
involved 59 patients with knee OA, randomized to receive single oral dose of 1,500 mg, 
GLU-SR and GLU-IR for 60 days with 31 and 28 patients, respectively. The equal 
efficacy of the glucosamine formulations on algofunctional indices in reducing pain in 
patients with knee OA with less number of adverse events (AEs) in GLU-SR.29 
 S.Mahendran et al (2011) .,formulated and evaluated the sustained release matrix 
tablets of glucosamine sulfate influence of combination of hydrophilic and hydrophobic 
matrix formers which can release the drug up to time of 24 h in predetermined rate. The 
combination of hydrophilic and hydrophobic combination showed less result than use of 
alone. The invitro release data was well fit to Peppa’s and Hixson Crowell release 
kinetics.30 
 Rikka mika et al (2005) .,formulated the controlled release tablets of N-acetyl-D-
glucosamine (NAG), maltose monohydrate and maltopentaose by using hydrophobic 
matrix formers starch acetate (SA) and ethyl cellulose (EC). The optimized matrices, 
which had either low porosity and high drug load or high porosity and low drug load, 
released the saccharides within the desired 2–4 h. In the case of sustained release 
formulations, it was found that the release of maltose monohydrate and maltopentaose 
was biphasic and slower than the release rate of NAG from similar tablets. Both SA and 
EC matrices were found to represent suitable controlled oral delivery vehicles for 
saccharides.31 
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2.2 LITERATURE REVIEW ON SUSTAINED RELEASE TABLETS:- 
 Sourabh jain et al (2008)., formulated the sustained release tablets of furosemide 
by using pectin, guar gum and xanthan gum. Invitro release of drug was performed in 
phosphate buffer PH 7.2 for 15hrs. The tablet with guar gum was found to be greater 
swelling than those with pectin and xanthan gum. It is cleared through the dissolution 
profile of furosemide from matrix tablet which was prepared using different natural 
polymers were retarded approximately 15h.32 
 V.N.Deshmukh et al (2009)., developed the sustained release metoprolol 
succinate tablet using natural hydrophillic gums such as karaya gum and xanthan gum as 
a release modifier and showed the mechanism of drug release of metoprolol succinate by 
the diffusion mechanism.33 
 Hamdy abdelkader et al (2009)., formulated the controlled release baclofen 
matrix tablet by using different types and levels of hydrophilic matrixing agents including 
methylcellulose (MC) sodium alginate (ALG) and sodium carboxymethylcellulose 
(CMC) in an attempt to formulate controlled release matrix tablet containing 25mg 
baclofen and that compared with standard commercial tablets and showed the excipients 
used in this study did not alter physico-chemical properties of the drug and the prepared 
matrix tablet showed good mechanical properties.34 
 Gangaraobattu et al (2011)., formulated the sustained release matrix tablet of 
lornoxicam for maintaining therapeutic blood or tissue levels of drug for extended period 
of time by using an natural polymer “Tamarind seed polysaccharide (TSP). The tablets 
were formulated by wet granulation method using 10%, 20%, 30%, and 40% of TSP as a 
binding agent. After 24h the release profile of tablets with 20% TSP binder shows 
maximum drug release with tablets containing 40% TSP by increasing the percent of 
natural polymer (TSP) release rate decreased. The formulation with 20% of TSP follows 
zero order kinetics via swelling, diffusion and erosion.35 
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 Afsar C.Shaikh et al (2011)., developed once-daily sustained release tablets of 
Aceclofenac sodium (200mg) by wet granulation using hydrophilic polymer like HPMC 
K100.The drug release of optimized formulations was shown to extend for 24h. The 
result showed that the release of drug can be extended by using suitable hydrophilic 
polymers in preparation of matrix based sustained release formulation of Aceclofenac.36  
 S.H. Lakade et al (2008)., formulated the Nicorandil matrix sustained release 
tablet which can release the drug up to time of 24 h in predetermined rate. The 
formulation of Nicorandil matrix tablet was prepared by the polymer combination of 
hydrophilic and hydrophobic in order to get required theoretical release profile. The 
invitro release rate profile should the higher concentration of F2 polymer in tablet, the 
combination of hydrophilic and hydrophobic combination showed less result than use of 
alone. The invitro release data was well fit to Peppa’s and Hixon crowel release 
kinetics.37 
 M.R.Bhalekar et al (2008)., formulated the sustained release matrix tablet of 
diclofenac sodium by using black gram as sustained release matrix forming material in 
formulation by wet granulation technique using isopropyl alcohol as a granulating agent.  
Sustained release matrix tablets of diclofenac sodium, were developed by using different 
drug: polymer ratios, such as BF1 (1:1), BF2 (1:2), BF3 (1:3) and BF4 (1:4). Tablets 
prepared with Hydroxypropylmethylcellulose (HPMC 50cps) and Xanthan gum as matrix 
forming material for the comparative study. The dissolution profiles of the HF2 (HPMC 
50cps) and XF1 (xanthan gum) matrix tablets were close to the profile obtained by seed 
flour of black gram based matrix tablets BF1 (black gram).The kinetic treatment showed 
that the release of drug follows zero order model and anomalous diffusion for BF1 and 
XF1 while the drug release of HF2 was best explained by Higuchi’s model and 
anomalous diffusion.The seed flour of black gram possess substantial matrix forming 
property that could be used for sustained drug delivery.38 
 Uttam mandal et al (2007)., formulated and optimized the sustained release 
matrix tablet of metformin HCL 500mg using response surface methodology by non-
aqueous wet granulation method using HPMC K15M and PVP K30 were used as matrix 
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forming polymer. The formulated tablets followed the higuchi drug release kinetics and 
diffusion was the dominant mechanism of drug release regulated the complete release 
within 8. Validation of optimization was performed, the percentage error of the mean was 
found to be (±S.D) 0.0437±0.385. By unraveling the study the effect of 2 factors on the 
invitro drug release helped in finding optimum formulation in sustained drug release.39 
 Shahanakhattak et al (2010)., formulated and evaluated controlled release 
matrix tablets of Losartan potassium using natural and synthetic polymers by direct 
compression method using different ratios of drug:polymer concentration. Fourier 
Transform Infrared Spectroscopy (FT-IR) and Differential Scanning Calorimetry (DSC) 
study revealed no chemical interaction between drug and polymers in a ratio of (1:1). 
Precompression and postcompression parameters complied with pharmacopoeial limit for 
the tablets. In-vitro release studies was performed and the results indicates that matrix 
tablet containing 50% w/w blend of natural and synthetic polymer has better controlled 
release for a period of 24 h.40 
 M.Harris shoaib et al (2006)., developed a once-daily sustained release matrix 
tablet of  Ibuprofen using hydroxypropyl methylcellulose (HPMC) as release controlling 
factor and to evaluate drug release parameters as per various release kinetic models. 
Sustained release profile tablets were directly compressed using Avicel pH 101 and 
Magnesium stearate. The formulated tablets were also characterized by physical and 
chemical parameters and results were found in acceptable limits. Different dissolution 
models were applied to drug release data in order to evaluate release mechanisms and 
kinetics. Criteria for selecting the most appropriate model was based on linearity 
(coefficient of correlation). The drug release data fit well to the Higuchi expression. Drug 
release mechanism was found as a complex mixture of diffusion, swelling and erosion.41 
 Bhupendra.G.Prajapatti et al (2010)., formulated and evaluated the novel 
nicorandil sustained release matrix tablet based on the combination of hydrophilic and 
hydrophobic matrix system. Formulated tablets were also characterized by parameters 
like thickness, weight variation test, drug content uniformity, hardness, friability and the 
invitro release rate profile was compared with the marketed product’s release profile with 
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the help of similarity factor (f2) value. Formulation prepared with HPMC K200M: 
Eudragit RSPO (1:1) indicates 94.46% of drug release at 22h and it has similarity factor 
(f2) value 68.07. Hydrophilic and Hydrophobic polymer combination showed 22h release 
using combination of hydrophilic or hydrophobic polymers.42 
 Margret Chandrin et al (2009)., formulated and evaluated the sustained release 
matrix tablets of Zidovudine by using different drug:polymer ratio. Kollidon SR, 
Hydroxy propyl methyl cellulose K15M, K100M as matrix former. All lubricated 
formulations were compressed by direct compression and by wet granulation method. 
Among the different formulation, B8 showed sustained release of drug for 12h with 
86.55% release. The regression coefficient value of Higuchi plot was found to be 0.9925 
that showed that drug was released by diffusion mechanism.Thus, drug in combination 
with Hydroxypropyl methylcellulose K100M were found to be effective in retarding the 
release of Zidovudine.43 
 Rakesh.K. Deore et al (2010)., formulated the oral sustained release matrix 
tablets of a mixture of both tramadol hydrochloride and glyceryl palmitostearate (GP) by 
melt granulation by direct compression (DC, 1:2 ratio). The MG4 showed the most 
suitable sustained release, 58.4 ± 1.1 % in 12 h (p < 0.05). Drug release (98.2 ± 0.2 % in 
8 h) was highest for direct compression which was prepared by direct compression. The 
Glyceryl palmitostearate is a suitable matrix-forming agent to sustain the release of a 
water-soluble drug such as tramadol hydrochloride.44 
 Inez Jimenez-Martinez et al (2008)., developed and formulated the in vitro 
sustained release of captopril from Metolose SH 4000 SR/sodium bicarbonate floating 
tablets. It has been studied, various proportions of Metolose and bicarbonate at two 
different compaction pressures. The results shows that matrices compacted at 55MPa 
float in the dissolution medium for more than 8 h while those compacted at 165MPa float 
only when sodium bicarbonate is included in the formulation. The increase of the matrix 
polymer proportion increases the maximal hydration volume as well as the time to attain 
this maximum. The matrices hydration volume increases with the inclusion of sodium 
bicarbonate in the formulation.45 
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 Eddy castellanos gil et al (2006)., developed and optimized the novel oral 
controlled delivery system  of propranolol hydrochloride (PPL).. The sustained-release 
matrix tablets with good physical, mechanical and technological properties were obtained 
with a matrix excipient:PPL ratio of 60:40 (w/w), with a dextran:HPMC ratio of 4:1 
(w/w) and with a cetyl alcohol amount of 15% (w/w). The value for the similarity factor 
(f2 = 69.6) suggested that the dissolution profile of the present two sustained-release oral 
dosage forms are similar. Higuchi (diffusion) and Hixon–Crowell (erosion) kinetic 
profiles were achieved and this codependent mechanism of drug releasewas established.46 
 A.Streubel et al (2002)., prepared and characterized single unit, floating 
controlled drug delivery systems consisting of (i) polypropylene foam powder, (ii) 
matrix-forming polymer(s), (iii) drug, and (iv) filler (optional). The highly porous foam 
powder provided low density and thus, excellent in vitro floating behavior of the tablets. 
All foam powder-containing tablets remained floating for at least 8 h in 0.1 N HCl at 37 
8C. The release rate was effectively modified by varying the ‘‘matrix-forming 
polymer/foam powder’’ ratio.The floating behavior of the low density drug delivery 
systems could successfully be combined with accurate control of the drug release 
patterns.47 
 Thomas quinten et al (2009)., developed the injection moulded matrix tablets by 
using a mixtures of ethyl cellulose and low substitutednhydroxy propyl methyl cellulose. 
Formulations containing metoprolol tartrate (30%, model drug), ethylcellulose with 
dibutylsebacate (matrix former and plasticizer) and L-HPC were extruded and 
subsequently injection moulded into tablets (375 mg, 10mm diameter, convex-shaped) at 
different temperatures (110, 120 and 130 ◦C). Tablets containing 30% metoprolol and 
70% ethylcellulose (EC 4cps) showed an incomplete drug release within 24 h (<50). The 
statistical design confirmed a significant influence of the EC and L-HPC concentration on 
drug release, while the processing temperature and EC viscosity grade did not affect drug 
release. 48 
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 S.I.Pather et al (1997)., formulated the sustained release theophylline matrix 
tablet by direct compression method by using ethylcellulose. In addition, matrices of this 
polymer display slow surface erosion which can be enhanced by the incorporation of a 
swelling agent. The release rate decreases because the external layers of the tablet 
become depleted and water must penetrate the deeper layers of the tablet to reach the 
remaining drug.. It was possible to sustain the release of a therapeutic dose of 
theophylline over a 12-h period. The erosion mechanism can be used to solve the 
problems associated with hydrophobic and plastic matrix tablets, i.e. the continuous 
reduction in the terminal release rate with time.49 
 Ghada ahmed abdel bary et al (2008)., developed an extended release matrix 
tablet of nicorandil; a freely water soluble drug used in cardiovascular diseases. Chitosan 
(CH)/hyaluronate sodium (HA), pectin (PE) or alginate sodium (AL) interpolymer 
complexes (IPCs) were prepared. The optimum IPCs (CH:HA, 40:60), (CH:PE, 30:70) 
and (CH:AL, 20:80) were characterized by Fourier transform infrared spectroscopy.. 
Nicorandil matrix tablets were prepared using the optimum IPCs, alone or in combination 
with Imwitor_ 900 K. Results of the dissolution studies revealed that formula F11 
(CH:AL, 20:80) IPC:Imwitor_ 900 K, 3:1) could extend drug release >8 h.50 
 N.Tanaka et al (2005)., formulated a novel sustained-release (SR) system for 
poorly water-soluble drug nilvadipine by applying solid dispersion (SD) technique for 
improving the solubility. The developed SR system, disintegration-controlled matrix 
tablet (DCMT), consists of hydrogenated soybean oil (HSO) as wax and SD granules 
containing low-substituted hydroxypropylcellulose (L-HPC) as a disintegrant. The 
release rate of NiD from DCMT was controlled by the disintegration rate of tablet. The 
release profile of NiD was described by the Hixson–Crowell’s model better than zero-
order kinetics, first-order kinetics and Higuchi’s model.51 
 S.Chopra et al (2007)., designed and optimized the sustained release dosage form 
of an anti-hypertensive agent, losartan potassium, using response surface methodology by 
employing a 3-factor, 3-level Box-Behnkenstatistical design. Independent variables 
studied were the amount of the release retardant polymers – HPMC K15M (X1), HPMC 
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K100M (X2) and sodium carboxymethyl cellulose (X3). In vitro release and swelling 
studies were carried out for the optimized formulation and the data were fitted to kinetic 
equations.The adjusted (0.9842) and predicted values (0.9893) of r2 for Y2 were in close 
agreement.. Tablets showed an initial burst release preceding a more gradual sustained 
release phase following a non-fickian diffusion process. 52 
 S.Orenetal et al (1996)., studied the anti-hypertensive efficacy of combination of 
verapamil SR/ trandolapril 180/l mg o.d. for a period of 8 weeks. The average systolic 
and diastolic blood pressure was reduced by a statistically significant amount (11/9 
mmHg) during the day) and 11/7 mmHg during the night (10.00 pm-8.00 am).. Two 
patients discontinued the study prematurely due to impotence which began during the 
placebo run-in period. No adverse events were serious or required any additional medical 
treatment. The fixed combination of verapamil SR and trandolapril appear to be a very 
effective and well-tolerated once-a-day antihypertensive medication.53 
 T.Kristmundsdottir et al (1996)., designed the release of diltiazem from 
eudragit microparticles by spraydrying technique using acrylate methacrylate 
copolymers. eudragit RS and RL as coating materials. The release pattern of diltiazem 
hydro chloride was affected by microparticles structure either as matrix or reservoir. The 
result shows that microparticles from eudragit acrylic resins RL and RS with a narrow 
particle size distribution. It is concluded that drug release rate can be controlled by 
polymer and spray drying technique.54 
 Harsh T Mulani et al (2011)., developed the characteristics of a new 
Polyvinylacetate/Povidone based excipient, Kollidon® SR were evaluated for application 
in extended release matrix tablets. The similarities in release profiles were evaluated by 
applying the model independent f2 similarity factor. A minimum concentration of 30% 
polymer was necessary to achieve a coherent matrix, able to extend the release of the 
incorporated drugs. Increasing the Kollidon® SR concentration in the tablet led to a 
slower drug release. Drug release follows square root of time dependent kinetics, thus 
indicating a diffusion-controlled release mechanism. It was concluded that Kollidon® SR 
is a potentially useful excipient for the production of pH-independent extended release 
matrix tablets.55 
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 Prajapati B.G et al (2010)., developed hydrophilic polymer and hydrophobic 
polymer based matrix Losartan potassium sustained release tablet which can release the 
drug up to time of 24 hrs in predetermined rate. Formulation of Losartan potassium 
matrix tablet was prepared by the polymer combination in order to get required 
theoretical release profile. In vitro release profile was checked for 24 hrs to evaluate the 
SR matrix tablet of Losartan potassium. From in vitro dissolution profile, Batch B4 was 
prepared with blend of HPMC K4M (67.2 mg), HPMC K200M (90mg) and Eudragit 
RSPO(112.5 mg), where drug release was about 94-98%. Batch B4 showed highest 
similarity factor values (f2 = 67.76).56 
 Nilesh.V.Ingle et al (2011)., developed the matrix tablets of Ambroxol 
Hydrochloride for Sustained Release.Hydroxy Propyl Methyl Cellulose (HPMC) K4M 
and Guar Gum as the retardant polymers and studied the effect of various formulation 
factors such as polymer proportion, polymer type and effect of filler type on the invitro 
release of the drug. In vitro release studies revealed that the release rate decreased with 
increase polymer proportion and hydrophobic polymers retard the drug release more than 
hydrophilic polymers. The formulations F7 sustained release of drug for 12 hrs with 
91.56%. Because of swelling property increased the drug release profile to a small extent 
due to change in swelling at the tablet surface. 57 
 M.Soumya et al (2011)., developed and optimized the bilayered sustained release 
matrix tablets of Valsartan. The tablets contained an immediate releasing layer with the 
loading dose of the drug and a sustaining layer with maintenance dose of drug prepared 
by wet granulation method. Sodium starch glycholate was used as super disintegrant and 
Eudragit RSPO and Eudragit RLPO were used as polymers. Formulation F9 was selected 
as an optimized one where the drug from immediate layer was released with in15 min 
and then sustained for a period of 12 hrs. Kinetic treatment to the invitro release data 
revealed that the drug release followed zero order non – fickian diffusion with n value 
greater than 0.45.58 
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S.Rajhans et al (2011)., designed a Swellable, gastro-retentive drug delivery 
system using combination of Polyethylene oxide (Polyox WSR 303) and HPMC K 
100LV by wet granulation process. Aging (by accelerated Stability study) showed no 
significant difference in dissolution when a sample packed in HDPE bottle was stored at 
40 ± 2°C / 75 ± 2 % RH conditions for 3 months. Based on the Release kinetics it can be 
concluded that this combination of Polyox WSR 303 and HPMC K 100 LV is particularly 
suitable as gastro retentive drug delivery system of Valsartan as extended release drug 
delivery system.59 
 Rajesh gollapudi et al (20011)., prepared a twice daily sustained release matrix 
tablets of losartannpotassium using Eudragit RLPO, RSPO and Ethyl cellulose 
individually and in combination of abovenpolymers.Matrix tablets assessed for their 
physicochemical properties and invitro drug release studies.  Invitro release data shows 
individual low polymer concentration of RLPO, RSPO sustain the drug release up to 
10hrs but combinations with EC sustain the drug release more than 12h.Eudragits in 
higher polymer proportion drug release was extend up to 12h. Ethyl cellulose has more 
retardation than Eudragits. Analysis of the release kinetics indicated that drug release 
mechanism was fickian diffusion.60 
 Huyen Thi Than et el (2011)., developed the sustained release (SR) tablets 
containing solid dispersions (SD) granules of a poorly water-soluble drug were prepared 
to investigate the controlled pH-independent release of the drug. Poloxamer 188 was used 
as an SD carrier. The SD granules dissolved completely within 10 min, a dissolution rate 
much higher than that of pure LST. Moreover, pH-independent sustained release of LST 
from the SD-SR tablet was achieved for 2 h in gastric fluid (pH 1.2) and for 10 h in 
intestinal fluid (pH 6.8). A combination of SD techniques using surface adsorption and 
SR concepts is a promising approachto control the release rate of poorly water-soluble 
drugs in a pH-independent manner.61 
 Shady M.Abed EL-Hali et al (2011)., designed oral controlled-release matrix 
tablets of SS using hydrophilic polymers. The effects of polymer concentration, polymer 
viscosity and binary mixtures of some polymers on the invitro drug release were studied. 
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The different prepared tablet formulae exhibited content uniformity within the acceptable 
limit and showed good mechanical properties. Increasing the polymer concentration from 
25% to 60%, as well as increasing HPMC viscosity resulted in significant retardation 
(p<0.05) of the drug release. The matrix tablets formulated using HPMC K100M and 
guar gum in a ratio of 1:1 succeeded to control drug release up to 80.8% in 12 h.62  
 Viena D.Dias et al (2007)., developed and designed the suitability of a 
hypromellose (HPMC) matrix system to achieve a bi-phasic releasebprofile: a fast release 
within 15 minutes (similar to an immediate release preparation) followed by extended 
drug release, using conventional tableting and coating technologies. In addition, the 
influence of a color top coat on drug release was investigated. Zolpidem tartrate, a non-
benzodiazepine hypnotic of the imidazopyridine class was selected as the model drug.63 
 A.K.Singhai et al (2011)., desinged and developed the controlled release (CR) 
matrix tablets of rifampicin by using Hydroxypropyl methylcellulose (HPMC) polymer 
(medium and high viscosity) by direct compression method. Influence of formulation 
variables such as drug: HPMC ratio, viscosity grade of HPMC on the formulation 
characters and drug release has been studied. The results indicated that the release rate of 
the drug and the mechanism of release from the HPMC matrices are mainly controlled by 
the drug: HPMC ratio and viscosity grade of the HPMC. The formulations were found to 
be stable and reproducible.64 
 Hiremath PS et al(2008)., carried out oral matrix tablet formulations for 
controlled release of anti-tubercular drugs like rifampicin, isoniazid using polymers 
HPMC, HPC(hydroxyl propyl cellulose) and Eudragit L100. They found that the proper 
combination of non-ionic and anionic polymers and a careful selection of formulation and 
process parameters could provide controlled release of rifampicin and isoniazid from a 
single matrix tablet. From their studies it was observed that the controlled release 
formulations containing 80% HPC and 60% Eudragit found to provide required release 
profile for both rifampicin and isoniazid. Thus, the optimized formulation of the present 
study provided both required initial release for rifampicin (80–100 mg) and isoniazid 
(36% of the dose) as loading dose and controlled release of rifampicin and isoniazid as 
maintenance dose from a single controlled release matrix tablet.65 
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 Hiremath PS et al (2008)., studied oral controlled release formulations of 
rifampicin and effect of formulation variables and process parameters on invitro release. 
The effect of HPMC viscosity, HPMC ratio, and rifampicin particle size on the release of 
rifampicin from CR matrix tablets. The above results indicated that the release rate of the 
drug and the mechanism of release were mainly controlled by the polymer 
viscosity/molecular weight and polymer ratio. The drug release could be extended from 
12h to beyond 24h by varying polymer ratio and viscosity character of the polymer.66 
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3.1 AIM OF THE WORK 
                 Glucosamine is an amino monosaccharide which is used for the treatment of 
osteoarthritis. Glucosamine is an essential component of mucopolysaccharides and chitin. 
Mucopolysaccharides (glycosaminoglycons) are large complexes of negatively charged 
carbohydrate chains that are incorporated into mucous secretions, connective tissue, skin, 
tendons, ligaments and cartilage. 
                   Glucosamine was administered orally as a Glucosamine salt get absorbed 
from the small intestine and it is transported via the portal circulation to the liver. 
Glucosamine is catabolized by first-pass metabolism in the liver and also by the gut 
metabolism. So to avoid this, Glucosamine has been taken in high dose to attain better 
bioavailability. An ingested tablet taken by the people for a long term, the major side 
effect suffered by the patients was tachycardia due to more concentration of drug in 
blood. Hence the present study is to release the drug in a required quantity to the body for 
that we planned to develop a sustained release formulation of Glucosamine 
hydrochloride. 
                    The success of a therapy depends on selection of the appropriate delivery 
system as much as it. Depends on the drug, sustained release dosage form are designed to 
complement the pharmaceutical activity of the medicament in order to achieve the better 
selectivity and longer duration of action.   
                  The aim of this present work is to formulate a Glucosamine Hydrochloride 
1500mg Sustained release matrix tablet by wet granulation method using polymers such 
as hydroxyl propyl methyl cellulose K100M and K200M, ethyl cellulose. The best 
formulation is to be selected on the basis of evaluation characteristics. 
                   To increase the residence time of the drug in the intestine and release the drug 
for a sustained period of time with following objectives; 
 Improve patient compliance. 
 Reduce dosing frequency. 
 Increase bioavailability of the drug.  
 To improve the efficacy of drug treatment. 
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3.2 PLAN OF WORK 
The present work was carried out to prepare Glucosamine Hydrochloride 
sustained release tablets and evaluate the invitro release of drug from the tablets. The 
stages involved in the plan of work are as follows. 
1. Construction of standard curve 
           2. Compatibility study between drug and selected polymers. 
• By Fourier Transform Infrared Spectroscopy. 
           3. Formulation of sustained release tablets 
           4. Evaluation of formulated tablets 
                  a) Physical parameters like thickness, weight variation, friability and hardness 
                b) Invitro drug release 
                c) Drug content uniformity 
                d) Selection of best formulations. 
                e) Stability Studies 
                f) Data analysis (drug release kinetics) 
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                                                                 Table no: 2   
                                                MATERIALS AND METHODS 
S.No Ingredients Manufacturer/Vendor 
1 
Glucosamine Hydrochloride USP               
(ASMF grade)  
Hygia health co ltd.,Mumbai 
2 
Calcium Hydrogen  Phosphate Anhydrous 
BP/Ph.Eur 
Enarchemi Private limited,Goa 
3 Hypromellose K200M BP/Ph.Eur Aqualon, Mumbai 
4 Ethocel 100 cps FP BP/Ph.Eur Dow Chemicals, Bangalore 
5 Sodium Alginate (NS Enteric ) Dow Chemicals, Bangalore 
6 Povidone BP/Ph.Eur K90F 
ISP International specialty products, 
Mumbai 
7 Hypromellose  K100M  BP/Ph.Eur Dow chemicals,Mumbai 
8 
Microcrystalline Cellulose BP/ Ph.Eur                       
PH102 
FMC Biopolymer,Bangalore 
9 Colloidal anhydrous silica  BP/Ph.Eur Cabot Sanmar Pvt. Limited., Mumbai 
10 Stearic acid  BP/Ph.Eur (50)                    Taurus chemicals (P) ltd.,Ahmedabad 
11 HypromelloseBP/Ph.Eur (HPMC E-5) Dow chemicals ,Bangalore 
12 Macrogol BP/Ph.Eur PEG 6000 
Manali petro chemicals  
Viswaat chemicals  
India glycols limited,Goa 
13 Opadry white IH OY-58900 Colorcon Asia Pvt.Ltd.Goa 
14 
Isopropyl alcohol BP/Ph.Eur Exxon/ Lee changyung 
Deepak fertilizers,Goa 
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Table no: 3 
                                INSTRUMENTS AND EQUIPMENTS  
S.No. Name of Instrument Manufacturer 
1 Digital Weighing balance Essaedigi,Germany 
2 Vibratory Sifter Ganson / Anchor, Bombay 
3 Multimill Ganson / Anchor, Mumbai 
4 Rapid high shear mixer granulator Ganson,Mumbai 
5 Fluid Bed Drier  Bectochem,Germany 
6 Octagonal Blender Ganson / Bectochem,Japan 
7 Tablet Compression machine Cadmach Machinery pvt. Ltd,Mumbai  
8 Vernier calipers Mitatoyo.China 
9 Friability apparatus Electrolab,Mumbai 
10 Hardness tester Varian,China 
11 Moisture balance EssaeTeroka,Mumbai 
12 Autocoater Neocota,Goa 
13 Digital pH meter Ecoscan,China 
13 Six station dissolution test apparatus Electro Lab, Lab India, Mumbai 
14 UV-Visible Spectrophotometer Shimadzu,Japan 
15 Stability chamber Osworld,Mumbai 
16 Sonicator Santorious flexit,Germany 
17 Bulk density apparatus Campbell electronics,Mumbai 
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4.3 Drug profile:- 67,68,69,70 
Glucosamine Hydrochloride:- 
                         Table no:4  Physico-Chemical characterizations 
S. No Parameter Observation 
1 Description White crystalline with odorless, slight sweet. 
2 Structure 
 
3 Molecular formula C6H13NO5.HCl 
4 IUPAC Name 
2-Amino-2-deoxy-D-glucopyranose 
hydrochloride (D-Glucose, 2-amino-2- 
Deoxy-, hydrochloride.) 
5 Molecular weight 215.63 
6 Category 
Osteoarthritis, Muscle Injury Prevention, 
Osteochondritis; Rheumatoid    Arthritis, 
tendonitis 
7 Solubility 
Soluble in water, but insoluble in organic 
solvent such as ethanol and faintly soluble in 
methanol. 
8 Melting point 190-to194 ºC 
9 Half-life (1.09 ± 0.98 h) 
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Description: - 
           Glucosamine Hydrochloride is an amino sugar and a prominent precursor in the 
biochemical synthesis of glycosylated proteins and lipids. A type of Glucosamine forms 
chitin, which composes the exoskeletons of crustaceans and other arthropods, cell walls 
in fungi and many higher organisms. Glucosamine is one of the most abundant 
monosaccharide. It is produced commercially by the hydrolysis of crustacean 
exoskeletons. Glucosamine is commonly used as a treatment for osteoarthritis, although 
its acceptance as a medical therapy varies. 
Bioavailability and Pharmacokinetic data:-   
Glucosamine is rapidly absorbed, highly distributed and efficiently cleared. Since 
the low bioavailability of the drug is evident only after oral administration, the gut rather 
than liver is implicated for an apparent large first-pass effect. 
After intravenous administration, the apparent terminal half-life (1.09 ± 0.98 h), 
apparent steady state volume of distribution (2.1 ± 1.1 L.kg-1) and total body clearance 
(2.61 ± 0.81 L.kg-1.h-1) were calculated. The peak plasma concentration, after oral 
administration, occurred approximately 30 min post-dose and the absolute bioavailability 
was 0.19. Glucosamine was completely bioavailable after intraperitoneal administration. 
Absorption:- 
             Glucosamine undergoes a rapid oral absorption. The absolute bioavailability of 
the drug by oral route was only 26% due to first-pass hepatic metabolism. 
Distribution:- 
            Glucosamine is not a protein bound but rather incorporates into plasma proteins 
(primarily globulins).The volume of distribution (Vd) of the drug was 2.5 lts. 
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Metabolism:- 
            Glucosamine hydrochloride is rapidly absorbed by oral or parenteral 
administration. It is metabolized (predominantly in the liver) to smaller molecules and 
ultimately to carbon dioxide, water and urea. 
Excretion:- 
             Scientific evidence for the safe use of glucosamine hydrochloride during 
lactation is not available. Approximately 11% of an orally administered dose of radio-
labelled glucosamine HCL was excreted in the feces; most of this appears to be 
unabsorbed drug. Less than 1% of radioactivity after radio-labeled intravenous or 
intramuscular doses appears in the feces.  
Mechanism of action: 
             The Precursor Supply Theory is the most popular explanation regarding the 
apparent beneficial effects of Glucosamine hydrochloride in Osteoarthritis. This theory 
states that Glucosamine hydrochloride supplies excess basic building blocks for the 
synthesis of cartilage glycosaminoglycans and/or bypasses rate-limiting steps in 
glycosaminoglycans synthesis.This is clinically relevant because it predicts that the non-
sulfated salts of Glucosamine (i.e., Glucosamine hydrochloride and N-acetyl 
Glucosamine) will be ineffective. 
As a result of extensive invitro testing, it is postulated that one or more alternate 
mechanism of action for Glucosamine hydrochloride in Osteoarthritis may include: 
• Squelching small signaling molecules such as Nitrous oxide and oxygen radicals 
that can damage articular cartilage. 
•  Exerting anti-inflammatory properties by decreasing prostaglandin E2 (PGE2) 
levels through suppression of cyclo-oxygenase-2 (COX-2) gene transcription16 or 
by increasing the production of hyaluronic acid in synovial fluid. 
• Mediating aggrecanase degradation of articular cartilage. 
• Exerting anticatabolic effects by decreasing expression, synthesis, or activity of 
matrix metalloproteinase’s (MMPs). 
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 Since the exact mechanism(s) of Glucosamine hydrochloride on cartilage 
metabolism remain to be elucidated and because high invitro doses are being used to 
study Glucosamine, extrapolation of findings to the invivo setting must be done with 
caution. 
ADVERSE EFFECTS:   
           In rare instances, some gastric discomfort was reported but was easily relieved by 
taking the supplement with food.  
DRUG INTERACTIONS:- 
            Glucosamine did not affect hemoglobin  in a randomized, double-blind, placebo-
controlled trial of 34 patients with well-controlled type 2 diabetes mellitus. The results of 
this trial may not apply to patients with uncontrolled diabetes .Glucosamine is likely safe 
for patients with diabetes that is well-controlled with it only or with one or two oral 
antidiabetic agents   
DOSE: 
            Most studies use 1500-2000 mg per day. 1500 mg per day is the most common 
dose. Dosages in the 3000 mg per day range have been used safely. Maintenance doses of 
750 to 1500 mg per day have been used. We recommend starting with 3000 mg per day 
of the Glucosamine capsules or powder for 1-3 months until some relief of pain has 
begun, then taper the dose down by 500-1000 mg per day until a maintenance dose is 
achieved between 1000 and 1500 mg per day. The 1000 mg capsules allow for a single 
daily dose in those who have achieved their level of maintenance pain relief.  
DOSAGE FORM: Tablet, Capsules, Oral powders, Ointments and Oral Liquids 
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4.4 EXCIPIENTS PROFILE71,72  
1. HYPROMELLOSE  
Non-proprietary name: Hypromellose, Hydroxypropylmethyl cellulose, 
Hypromellose. 
Synonyms: Benecel MHPC, E464 Hydroxypropylmethyl cellulose HPMC, Cellulose 
Hydroxypropylmethyl ether 
Chemical name: Cellulose Hydroxypropyl methyl ether. 
Structural formula: 
   
Molecular weight: 10,000 – 1,500,000. 
Functional category: Film former, Rate controlling polymer for sustained release, 
Viscosity – increasing agent.  
Pharmacopoeia: BP, Eur. Pharmacopoeia, and USP. 
Description: Odorless, tasteless, White or creamy white colored, fluffy, acid, 
hygroscopic powders with slight characteristics odor. 
Aqueous viscosity: Methocel K100M: 1, 00,000 mPas. 
Solubility: Soluble in cold water forming viscous colloidal solution. 
Stability and storage condition: Stable at room temperature should be store in 
airtight container in a cool and dry place.  
Incompatibilities: Hypromellose are incompatible with some oxidizing agents. 
Application: It’s used in oral ophthalmic and topical   preparations. They are mainly 
used as the matrix in sustained release formulation 
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2. ETHYL CELLULOSE  
Non proprietary name: Ethyl cellulose, Ethyl cellulose. 
Synonyms: Aqua coat ECD, Aqualon E462, Ethocel, surelease. 
Chemical name: Cellulose ethyl ether. 
Structural formula: 
 
Functional category: Coating agent, flavoring fixative, tablet binder, tablet filler, 
Viscosity- increasing agent. 
Pharmacopoeia: Ph.Eur. BP and USP. 
Description: Tasteless, free-flowing, white to light tan-colored powder. 
Viscosity: EthocelStd 100 FP: 90-110 mPas. 
Solubility: Freely soluble in chloroform, methyl acetate, and tetrahydrofuran, 
partially soluble in water. 
Storage condition: It’s stable but slightly hygroscopic in nature. Ethyl cellulose are 
stored at temperature not exceed 32 o c in dry area away from all sources of heat. 
Application: Mainly used as a matrix forming material in sustained release 
formulation. It’s also used as a film forming controlling releasing agent in coating. 
USES: 
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3.  SODIUM CARBONATE  
Non proprietary name: Sodium Alginate  
Synonyms: Alginatesodico; align; alginic acid, sodium salt; E401; Kelcosol;  
Keltone; natriialginas; Protanal; sodium polymannuronate. 
Chemical name: Sodium alginate 
Structural formula:  
                                                  
Functional category: Stabilizing agent; suspending agent; tablet and capsule 
Disintegrant, Tablet binder; viscosity increasing agent. 
Pharmacopoeia: Ph.Eur. BP and USP.  
Description: Sodium alginate occurs as an odorless and tasteless, white to pale 
yellowish-brown colored powder. 
Viscosity: A 1% w/v aqueous solution, at 208C, will have a viscosity of 20–400 mPas  
Solubility: Practically insoluble in ethanol (95%), ether, chloroform, and 
ethanol/water mixtures in which the ethanol content is greater than 30%. Slowly 
soluble in water, forming a viscous colloidal Solution 
Storage condition: Sodium alginate is a hygroscopic material, although it is stable if 
stored at low relative humidities and a cool temperature.  
Application: It is mostly used as Disintegrant and binder in tablet formulation. 
Diluents in capsule formation, preparation of sustained –release oral formulation it 
will delay the dissolution of the drug, thickening and suspending agent in gels, cream 
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4.  ANHYDROUS CALCIUM HYDROGEN PHOSPHATE
Non proprietary name:  
calcium phosphate, Calcium
phosphate. 
Synonyms: A-TAB; calcium monohydrate phosphate; calciu
Cafos AN; Dicalcium orthophosphate; E341; Emcompress Anhydrous; Fujicalin.
Chemical name: Dibasic calcium phosphate
Structural formula: 
                                      
 
Molecular weight: 136.06 
Functional category: Tablet and capsule Diluents.
Pharmacopoeia: BP, Eur. Pharmacopoeia, JP and USPNF.
Description: Anhydrous dibasic calcium phosphate is a white, odorless, tasteless 
Powder or crystalline solid. It occurs as triclinic crystals
Solubility: Practically insolu
Stability and storage condition:
nonhygroscopic, relatively stable material. Under conditions of high humidity it does 
not hydrate to form the dehydrate. 
Incompatibilities: Calcium hydrogen phosphate is incompatible with tetracycline 
antibiotics. 
EXCIPIENTS PROFILE
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Application: Dibasic calcium phosphate anhydrous is widely used in oral 
pharmaceutical products, food products, and toothpastes, dentifrice formulation also 
used as abrasive and lubricant. 
5. POVIDONE 
Non proprietary name: 
Synonyms: E1201, Kollidon, plasodone, Polyvidon, Polyvinylpyrrolidone, pvp.
Chemical name: 1- ethenyl
Structural formula: 
                                         
Molecular weight: 2500 
Functional category: Disintegrant, dissolution aid, suspending agent and tablet 
binder. 
Pharmacopoeia: BP, Eur. Pharmacopoeia, JP and USP.
Description: Fine, white to creamy 
Aqueous viscosity: Povidone K90 
Solubility: Freely soluble in acids chloroform, ethanol and water but insoluble ether 
and mineral oils. 
Stability and storage condition
sterilization of the aqueous solution does not alter its
well-closed container, in a cool and dry place.
Incompatibilities: Incompatible with some in
resins and other chemicals. Preservative like thimerosal may forms complex with 
Povidone. 
EXCIPIENTS PROFILE
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Application: Povidone is widely used as a binder in wet granulation, solubizing agent 
in oral or parenteral preparation
agent. 
 
6. MICROCRYSTALLINE CELLULOSE
Non proprietary name:
Cellulose, Microcrystalline Cellulose
Synonyms:Avicel PH; Cellets; Celex; cellulose gel; hellulosum 
Celphere; Ceolus KG; crystalline cellulose; E460; Emcocel; Ethispheres; Fibrocel; 
MCC Sanaq; Pharmacel; Tabulose; Vivapur.
Chemical name: Cellulose
Structural formula: 
 
 
 
 
Molecular weight: 36 000
Functional category: Adsorbent; suspending agent; tablet and capsule 
tablet disintegrate. 
Pharmacopoeia: BP, Eur. Pharmacopoeia, JP and USP, NF.
Description:  Purified, partially depolymerized cellulose that occurs as a white, 
odorless, tasteless, crystalline powder 
commercially available in different particle sizes and moisture grades that have 
different properties and applications
Solubility: Slightly soluble in 5% w/v sodium hydroxide solution; practically 
insoluble in water, dilute acids, and most organic solvents.
EXCIPIENTS PROFILE
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Stability and storage condition: Microcrystalline cellulose is a stable though 
hygroscopic material. .The bulk material should be stored in a well-closed container 
in a cool, dry place 
Incompatibilities: Microcrystalline cellulose is incompatible with strong oxidizing 
agents 
Safety: It is generally regarded as a nontoxic and non-irritant material, having little 
toxic potency. In deliberate abuse formulation has result in cellulose granulomas. 
Application: Microcrystalline cellulose is widely used in pharmaceuticals, primarily 
as a binder/Diluents in oral tablet and capsule formulations where it is used in both 
wet-granulation and direct-compression processes. In addition to its used as a 
binder/Diluents’, microcrystalline cellulose also has some lubricant and disintegrant 
properties that make it useful in tableting.  
 
7. COLLOIDAL SILICON DIOXIDE 
Non proprietary name: Colloidal Anhydrous Silica   Light Anhydrous Silica Acid 
Silica, Colloidal Anhydrous Colloidal Silicon Dioxide 
Synonyms:Aerosil; Cab-O-Sil; Cab-O-Sil M-5P; colloidal silica; fumed silica; fumed 
silicon dioxide; hochdispersessilicumdioxid; SAS; silica colloidalisanhydrica; silica 
sol; silicianhydride; silicon dioxide colloidal; silicon dioxide fumed; synthetic 
amorphous silica; Wacker HDK. 
Chemical name:Silica 
Structural formula:  SiO2 
Molecular weight: 60.08 
Functional category: Adsorbent; Anticaking agent; emulsion stabilizer; glidant; 
suspending agent; tablet Disintegrant; thermal stabilizer; viscosity-increasing agent. 
Pharmacopoeia: BP, Eur. Pharmacopoeia, JP and USP, NF. 
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Description: Colloidal silicon dioxide is submicroscopic fumed silica with a particle 
size of about 15 nm. It is a light, loose, bluish-white-colored, odorless, tasteless, 
amorphous powder.  
Solubility: Practically insoluble in organic solvents, water, and acids, except 
hydrofluoric acid; soluble in hot solutions of alkali hydroxide. Form a colloidal 
dispersion with water. For aerosil, solubility in water is 150 mg/L at 258C (pH 7). 
Stability and storage condition:-Colloidal silicon dioxide is hygroscopic but adsorbs 
large quantities of water without liquefying should be stored in a well-closed 
container 
Incompatibilities: Incompatible with diethylstilbestrol preparations.  
Safety: It is generally regarded as a nontoxic and non-irritant material; however, 
intraperitoneal and subcutaneous injection may produce local tissue reactions and/or 
granulomas. Colloidal silicon dioxide should therefore not be administered 
parenterally. 
Application 
• Colloidal silicon dioxide is widely used in pharmaceutical industries, food 
products, and in cosmetics. 
• Helps in increase the flow properties of the dry power. 
• Used as stabilizer in suspension, thixotropic thickening and suspending agent 
in gels.    
• Also used as tablet disintegrate, and as adsorbent in wax micro spheres. 
 
8. STEARIC ACID 
Non proprietary name: Stearic acid, Acidumstearium. 
Synonyms: Cethlacetic acid, crodacid E570, Edenor, Emersol, Hystrene, Kortacid 
1895. 
Chemical name: Octadecanoic acid. 
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Structural formula: 
                                  
Molecular weight: 284.47 
Functional category: Emulsifying agent, solubizing agent, Tablet and capsule 
lubricant. 
Pharmacopoeia: BP, Eur. Pharmacopoeia, JP and USPNF.
Description: Hard, white or faintly yellow 
solid or white or yellowish white powder with slight odor and taste suggesting tallow.
Solubility: Freely soluble in benzene, carbon tetrachloride, chloroform and ether also 
insoluble in water. 
Stability and storage condition:
some antioxidant may be used. Should be stor
a cool and dry place. 
Incompatibilities: Stearic acid is incompatible with most metal hydroxides and 
oxidizing agents. 
Application: Stearic acid is widely used in oral and topical pharmaceutical 
formulation. It has also been mainly used in oral preparation of tablets or capsule as 
lubrication and also as a binder.  It’s also used in cosmetic and food products.
EXCIPIENTS PROFILE
 
 
(for pure material) 
 
– colored, somewhat glossy, crystalline 
 It is a stable material but in case of bulk materials 
ed in a well closed container and 
 
Page 56 
 
kept in 
 
EXPERIMENTAL INVESTIGATION 
 
DEPT OF PHARMACEUTICS, KM COLLEGE OF PHARMACY Page 57 
 
5.1 Construction of Standard curve of Glucosamine Hydrochloride:- 
Dervitization of Glucosamine Hydrochloride: 73, 74   
0.2 M Borate buffer:  
 About 7.63 g of sodium borate was weighed and transferred into a 100ml 
volumetric flask containing 80 ml of distilled water, adjust to a pH of 9.5 with 
hydrochloric acid and volume was made upto 100ml with solvent and mixed well.   
Derivitizing reagent:  
 About 0.2g of o-phthalaldehyde was weighed and transferred into a 100ml 
volumetric flask, dissolved in 5 ml of anhydrous methanol sonicated for 10 minutes to 
this 0.2ml of 3-mercaptopropionic acid and 45 ml of 0.2 M Borate buffer was added 
and mixed gently, volume was made upto 100ml. The reagent was placed in the dark 
for 30minutes before using.  
Procedure:-  
a) Preparation of primary stock solution:- 
            About 150mg of drug was weighed and transferred into a 100ml volumetric 
flask containing distilled water and volume was made upto 100ml from that 2 ml was 
pipetted out and transferred into 50ml volumetric flask and volume was made upto 
50ml with distilled water. 
b) Preparation of secondary stock solution:- 
 From the primary stock solution 5ml was pipetted out and transferred  to a 
20ml  volumetric flask,  to this  2ml of derivatizing reagent was  added and volume 
was made upto 20ml with distilled water . 
5.1.4. Standard spectrum of Glucosamine Hydrochloride SR tablets75      
 About 150mg of drug was weighed and transferred into a 100ml volumetric 
flask, volume was made upto 100ml with distilled water from this solution 2 ml was 
pipetted out into a 50ml volumetric flask, volume was made upto 50ml again from 
this solution 5ml was pipetted out and transferred into a 20ml volumetric flask to this 
add 2 ml of derivatizing reagent and volume was made upto 20ml with distilled water. 
The spectrum was taken in the range of 200 to 400 nm. The λmax was found to be 
205nm. 
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5.1.5. Standard curve of Glucosamine hydrochloride:-75 
Standard curve of Glucosamine hydrochloride was carried out by using the 
different concentrations. 100 mg of drug was dissolved in 100 ml of distilled water 
and from that, further dilution was made in different concentration of 5µg/ml, 
10µg/ml, 15µg/ml, 20µg/ml, 25µg/ml, 30µg/ml .Their absorbance are observed at 205 
nm using derivatizing reagent and the graph has been plotted between Absorbance Vs 
Concentration.  
 A standard graph was plotted by keeping the known concentration on x-axis 
and obtained absorbance on y-axis. 
 
Table no: 5  Data for Standard curve 
Standard curve of Glucosamine hydrochloride SR Tablets 
Concentration(µg/ml) Absorbance 
5 0.156 
10 0.321 
15 0.468 
20 0.624 
25 0.779 
30 0.936 
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5.2 Preformulation studies
                        Preformulation studies can be defined as an investigation of physical 
and chemical properties of active pharmaceutical ingredient, alone and in combination 
with excipients. The objective of Preformulation studies is to generate info
useful to the formulator in developing stable and bioequivalent dosage form that can 
be mass- produced. 
• Preformulation testing is an investigation of physical and chemical properties 
of drug substances alone and when combined with excipients. It is
step in the rational development of dosage forms. 
• The overall objective of preformulation testing is to generate information 
useful to the formulation in developing stable and bioavailable dosage forms. 
• The use of preformulation parameters max
an acceptable, safe, efficacious and stable product. 
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• The drug (Glucosamine Hydrochloride) in powder form and granules were 
subjected to the following physical test for 3 times and average values were 
noted. 
5.2.1Derived properties:-76 
a) Bulk density:- Bulk density is defined as a mass of a powder divided by the bulk 
volume. 
A sample powder of Glucosamine Hydrochloride (10 g) was introduced in 100 
ml graduated cylinder. The volume of the material was noted on graduated cylinder. 
The bulk density was calculated by the formula given below; 
                            Bulk density (ρ0) = M/Vo 
Where,  M = mass of the powder  
                                Vo = volume of the powder  
b) Tapped Density:-  
The powdered sample was screened through sieve no: 18 and the weight of 
sample equivalent to 10 g were filled in 100 ml graduated cylinder. The mechanical 
tapping of the cylinder was carried out at a rate of 300 drops per minute for 500 times 
from 3” height and the tapped volume Vf was noted. The tapped density was 
calculated in gm/ cm3 by the formula, 
                                Tapped density (ρt) = M/Vf 
 Where,           M = weight of sample powder taken 
                                Vf = tapped volume 
c)  Compressibility Index: 
The bulk density and tapped density was measured and compressibility index 
was calculated using the formula, 
           C.I. = {(ρt-ρo)/ρt} ×100 
Where,  
                                    ρt = tapped density 
                 ρo = bulk density 
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d) Hausner’s ratio: 
Tapped density and bulk density were measured and the Hausner’s ratio was 
calculated using the formula, 
   Hausner’s ratio = ρt/ρ 
Where, 
                 ρt = tapped density   
                                    ρo = bulk density 
 5.2.2 Infrared Spectroscopic studies:-74 
            Identification of the pure drug and polymer were performed using infrared 
spectroscopy. 
            IR spectroscopy (using Perkin Elmer) by KBr pellet method was carried out 
on drug and polymer. They are compressed under 10 tones pressure in a hydraulic 
press to form a transparent pellet. The pellet was scanned from 4000 to 400cm-1 in a 
spectrophotometer and peaks obtained were identified. 
5.2.3Drug Excipient compatibility studies:- 
           Binary mixtures of drug and excipients in the ratio 1:1 by trituration were 
prepared and packed in glass vials. All the samples were kept in 40oC/75%RH storage 
conditions for 1 month. The samples were observed for color change at a frequency of 
7 days for a period of one month. 
• The drug and the excipients were also mixed in 1: 1 ratios and was kept in 
40oC/75% RH for 1 month  
• The drug and the excipients were triturated with IPA as granulation solvents 
kept in 40oC/75% RH for period of 1 month. 
Compatible Excipients: 
 Based on the drug: excipients compatibility study, the following excipients 
were considered as compatible and used in the present product development. 
 Dicalcium phosphate anhydrous ( DC grade ,unmilled , A-TAB)  
 Ethyl Cellulose. 
 Stearic Acid (Powder) 
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 Isopropyl Alcohol 
 Microcrystalline Cellulose. 
 Opadry white OY 58900 
 Opadry white OY 85f18422 
 Colloidal anhydrous silica 
 HPMC K100M and K200M. 
5.3 Formulation of Glucosamine hydrochloride:- 
          Glucosamine hydrochloride sustained release tablets were prepared by using 
wet granulation method. The hydoxy propyl methyl cellulose, calcium hydrogen 
phosphate anhydrous, microcrystalline cellulose powder, active ingredient and 
povidone k90 solution are mixed homogeneously. Like that hypromellose K200M 
was used instead of K100M for another batches. The blend was placed in the rapid 
mixing granulator inorder to prepare the granules  and then  dried in the fluidized bed 
dryer at a temperature of 550C.The granules are passed #20mesh, stearic acid was 
added as a lubricant. The dried granules were compressed in 27 stationary double 
rotary punching machine into tablets by using 22x11mm oval shaped punch. 
5.3.1 Design and composition of formula:-77 
 The design of tablets is an important part of the formulator, to produce a 
product with desired properties. It involves the correct selection and balance of 
excipient for active ingredients to achieve the desired response.  
Based on primary information on the uncoated and coated tablets and previous 
experience with the manufacturing of various products, the following tentative 
product specifications were proposed before starting the formulation trials. 
5.3.2Justification for the design of the composition: 
  In addition to the active, Glucosamine Hydrochloride 1500mg SR tablets 
contained a number of inert materials as diluents, binders, glidant, lubricants and 
coating polymers to impart satisfactory processing, compression and release 
characteristics to the formulation. The justification for the inclusion of these 
functional additives is briefly described below: 
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a. Diluents:  
 They are inert materials added to increase the bulk in order to make the tablet 
with a desired particle size for compression. Calcium Phosphate anhydrous, 
Microcrystalline Cellulose was used in the present development as directly 
compressible materials.  
b. Binders:  
  Materials used to impart cohesive quality to the powdered materials are 
referred to as binders. They impart cohesiveness to the tablet formulation which 
ensures the tablet remaining intact after compression as well as improving the free 
flowing qualities by the formulation of granules of desired hardness and size.  In the 
present study Povidone K 90 was selected as binder.  
c. Lubricants:  
 They prevent the adhesion of the tablet material to the surface of the dies and 
punches reducing inter-particle friction, facilitating the ejection of the tablet from the 
die cavity and improve the rate of flow of the tablet granulation.   
 Stearic acid was used as lubricant which is in hydrophobic in nature and it is a 
proper choice as the tablet  does not shows any tendency to stick to the side of the die. 
The tablets were found to be satisfactory and the dissolution profile of the drug 
substance was satisfactory with the use of Stearic acid.  
d. Coating formula components:  
   The core tablets were coated with a film coating consisting of the film formers 
Opadry WhiteOY 58900, HPMC E-5 and PEG 6000 as processing aid. 
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Table no: 6   Formulation Details 
Inactive Ingredient Category  Concentration per tablet 
Core Ingredients 
Calcium hydrogen 
phosphate anhydrous 
Diluent 2-4% 
Povidone K90F Binder 2-3% 
Hypromellose K200M Polymer 2.55% 
Hypromellose K100M Polymer 5-8% 
Micro Crystalline Cellulose Diluent 2-5% 
Colloidal silicon dioxide Glidant 0.27-0.97% 
Stearic Acid Lubricant 1.08-2.16% 
Coating Ingredients 
Opadry White OY 58900 Color 0.59% 
Opadry white OY 85f18422 Color 0.48-0.59% 
Hypromellose E-15 Thickener 0.052-0.27% 
Propylene glycol Plasticizer Qs 
Isopropyl Alcohol Solvent Qs 
Purified Water Solvent Qs 
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5.3.3 Manufacturing procedure for Glucosamine hydrochloride SR tablets:-78 
Step 1: Dispensing: All the materials are dispensed. 
Step 2: Sifting: 
a) The materials Glucosamine Hydrochloride, Hypromellose K 200M, was sifted 
through #40 mesh and collected separately into polyethylene bags. 
b) The extra granular materials like Glucosamine Hydrochloride, Hypromellose 
K 200M, Colloidal Anhydrous Silica was sifted through # 40 mesh and 
collected separately in double lined poly bag. 
c) The stearic acid was sifted through # 40 mesh and collected separately in a 
double lined polybag. 
Step 3: Binder solution preparation: 
 The required quantity of purified water was taken into a suitable stainless steel 
vessel and required quantity of Povidone k 90 F was added (Binding solution) and 
stirred well by using magnetic stirrrer. The stirring was continued until the clear 
solution was formed.  
Step 4: Granulation:    
 The presifted materials of STEP 2(a) was loaded into a rapid mixing 
granulator and mixed for 5 minutes with impeller at slow speed.  
Step 5: Binder addition: 
 The binder solution was added to step 3 gradually to the dry mix for 1 – 5 
minutes with impeller at slow speed.   
Step 6: Kneading: 
            After complete addition of binder, the mixing was continued for 10 sec to 1 
minute with impeller and chopper at high speed. The impeller and chopper were 
switched off. The granules were taken and visually observed for the consistency of the 
granules and the wet mass was loaded into the fluidized bed dryer bowl. 
Step 7: Drying:- 
            The inlet temperature was set at 45°C (Limit: 40°C - 50°C) and the granules 
were dried for 10 minutes repeatedly until the moisture content reaches the limit. 
EXPERIMENTAL INVESTIGATION 
 
DEPT OF PHARMACEUTICS, KM COLLEGE OF PHARMACY Page 66 
 
Step 8:- Sifting and Milling: 
1. The dried granules were sifted by using vibratory sifter fitted with #20 mesh 
and the retained granules are taken into a respective double lined polyethylene 
bags. 
2. The retained granules are milled by using multi mill fitted with 1.5 mm screen 
in knives forward direction at medium speed and collected into a double 
polyethylene bag. The milled granules were passed through #20 mesh, again 
the retained granules are milled through 1.0mm screen. Then the milled 
granules are passed through #20 mesh and collected in a double lined 
polyethylene bags. 
STEP 9: Blending: 
             The sized granules and the sifted extra granular materials Glucosamine 
Hydrochloride (part II), Hypromellose K100M, Microcrystalline Cellulose pH102 and 
Colloidal anhydrous silica are loaded into a octagonal blender and blended for 10 
minutes. 
STEP 10: Lubrication:  
  Sifted Stearic acid was loaded into the blender and blended for 5 minutes 
STEP 11: Compression: 
 Lubricated blend was compressed in 22x11 mm oval shaped bevel ledge 
punch with average weight of 1985mg.  
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Table no: 7 Formulation composition (in mg) 
 
Formula composition 
S.No Ingredients Batch no: F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 
 Dry mix           
1 Glucosamine hydrochloride 1500 1500 900 1500 900 900 900 900 900 900 
2 Ethyl cellulose 45cps    115 90 - - - - - -    - - 
3 Hypromellose K100M 100 100 - - - - - - -    - 
4 
Di-Calcium phosphate 
anhydrous 90 115 62 27 27 - 60 40 - - 
5 HypromelloseK200M - - 40 40 40 123 162 40 200 300 
6 Ethyl cellulose100cps - - - 55   55 82 -     - - - 
 Binder           
7 PovidoneK30 20 20 -    - - - - -     - - 
8 PovidoneK90F - - 40 40 40 40 40 40   70 70 
9 Purified water qs qs -    - qs qs qs qs    qs qs 
10 Isopropyl alcohol - - qs    qs - - - -     - - 
 Extra-granular           
11 Glucosamine hcl - - 600     - 600 600 600 600 600 600 
12 HypromelloseK100M - - 80     - - 110 - 100 - - 
13 HyprmelloseK200M - - -     - 60 65 60 -   70 70 
14 
Microcrystalline 
cellulosePH102 - - 83   83 83 - 60 70    - - 
15 Colloidal anhydrous silica - - -    - 5 5 18 -    5 5 
 Lubrication           
16 Stearic acid - - 40   40 40 20 18 20     40 40 
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Table no: 8     COATING COMPOSITION 
S.No Film coating (Layer I) F6 F7 F8 F9 F10 
    1 Hypromellose(HPMC E-5) - - 9.00 9.00 9.00 
    2 PEG 6000(Macrogol) - - 1.00 1.00 1.00 
    3 Isopropyl alcohol - - qs qs Qs 
    4 Purified water - - qs qs Qs 
 Film coating (Layer II)      
    5 Opadry white  OY-58900 25.00 - 11.00 - - 
    6 Opadry white  85f18422 
- 25.00 - 16 16 
    7 Purified water qs qs qs qs Qs 
 
Invitro Dissolution studies:-79 
 Invitro drug release studies of Glucosamine Hydrochloride was studied by 
using dissolution apparatus USP typeII paddle method with a stirring speed of 50rpm 
at 370C ±0.50C in distilled  water for 2 h and in 900ml of dissolution media. The 
samples were taken at preselected time intervals with replacement of equal volume of 
dissolution media. The collected samples were diluted and the absorbance was 
measured spectrophotometrically at 205nm.The percentage of Glucosamine 
Hydrochloride release at various time intervals were calculated from the standard 
graph. 
 
5.4 Evaluation of Glucosamine Hydrochloride granules:- 
 All the formulated Sustained Release tablets were evaluated for following 
parameters 
5.4.1 Content uniformity of dosage form by Mass variation method: 81 
 The assay was carried out for the active substance(s) on a representative 
sample of the batch using an appropriate analytical method, this value was result A, 
expressed as percentage of label (as given below). Assumed that the concentration 
(mass of active substance per mass of dosage unit) was uniform.  
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 Procedure:- 
  The 10 tablets we
content, expressed as percentage of label claim, of each tablet from the mass of the 
individual tablets and the result of the assay, c
5.4.2 Acceptance value:-
       Calculated the acceptance value (
contents of the units are replaced with the individual estimated contents defined 
below.  
x1, x2... xn = individual estimated contents of the dosage units tested, 
   where,    
w1, w2... wn = individual masses of the dosage units tested;  
A = content of active substance (percentage of label claim) obtained using an 
appropriate analytical method (assay); 
the assay.   
Calculation of Acceptance value:
   Calculated the Acceptance Value (
                                                    
Acceptance Criteria:  
  (1) Acceptance value (AV) =
Where,  
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re weighed individually. Calculated the active substance 
alculated the acceptance value.
82 
AV) as shown below, except that the individual 
 
 
  
 
 = mean of individual masses of the units used in 
 
AV) using the formula 
 
  
 | M - X | + ks.      
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            k = Acceptability constant      
 If the number of tablets tested is 10, then k= 2.4     
 If the number of tablets tested is 30, then k= 2.0     
 s = Sample standard deviation.  
(2) Calculated the mean of the individual contents (expressed as % of label claim) and        
        note down as X.  
(3) Determined the value of M as follows. 
   (i)  If 98.5% ≤ X ≤ 101.5% then M = X     
(ii)  If X < 98.5% then M= 98.5%        
(iii) If X > 101.5%   then M = 101.5%  
 The requirements for dosage uniformity were met if the acceptance value of the 
first 10 dosage units is less than or equal to L1 (L1=15.0). 
 If the acceptance value is greater than L1, test additional 20 units and calculated 
the acceptance value. The requirements are met if the final acceptance value of the 30 
dosage units is less than or equal to L1, and no individual content of any dosage units is 
less than Acceptance Value. L2 is 25.0. 
5.4.1Evaluation of blend characteristics of Glucosamine Hydrochloride:-83 
a) Angle of repose. 
In order to determine the flow property, the Angle of repose was determined. 
It is the maximum angle that can be obtained between the free standing surface of the 
powder heap and the horizontal plane. 
               Ө = tan -1 (h/r) 
            Where,      
                                          h=height,r=radius 
                                         Ө = Angle of repose 
Procedure 
• An accurately weighed sample was taken. 
• A funnel was fixed in the stand in such a way that the tip of the funnel was at 
the height of 6 cm from the surface. 
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• The sample was passed through the funnel slowly to form a heap. 
• The height and the circumference of the powder heap formed were measured. 
• The radius was measured and the angle of repose was determined using the 
above formula. This was repeated five times for a sample 
 
 
 
           Table no: 9 Flow properties of powders and their angle of repose 
Angle of repose in degree Flow Property 
<25 Excellent 
25-30 Good 
30-40 Passable 
>40 Very poor 
 
b)  Determination if Bulk density and Tapped density:83 
A quantity of 5g of the powder (W) from each formula was introduced into a 
25 ml measuring cylinder. After the initial volume was observed, the cylinder was 
allowed to fall under its own weight onto a hard surface from the height of 2.5 cm for 
duration 2  intervals. The tapping was continued until no further change in volume 
was noted. The bulk density, and tapped density were calculated using the following 
formula. 
                          Bulk density = W / VO,  
                         Tapped density = W / Vf 
Where, 
                                     W = weight of the powder,  
                                     VO = initial volume,  
                                     Vf = final volume 
c)  Hausner’s ratio:-83 
         It indicates the flow properties of the powder and is measured by the ratio of 
tapped density to the bulk density.  
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                                Hausner’s Ratio = Tapped density/Bulk density                                         
Table no:10 Flow property by Hausner’s ratio 
S.No Hausner’s Ratio Property 
1 0-1.2 Free flowing 
2 1.2-1.6 Cohesive powder 
d)  Compressibility index (Carr’s index).83 
Compressibility index is an important measure that was obtained from the 
bulk and tapped density. In this theory, the less compressible material has the more 
flowable. A material having values of less than 20 to 30% was taken as the free 
flowing material.  
              
100
density  Tapped
density Bulk desnity Tapped
 index  sCarr' ×
−
=
 
                  Table no: 11 Compressibility and flow property relationship 
% Compressibility Index Properties 
5-12 Free flowing 
12-16 Good 
18-21 Fair 
23-35 Poor 
33-38 Very poor 
>40 Extremely poor 
 
5.5 Evaluation of Sustained release Tablets:-83 
5.5.1 General Appearance:- 
The general appearance of a tablet, its identity and general elegance was 
essential for consumer acceptance, for control of lot-to-lot uniformity and tablet-to-
tablet uniformity. The control of general appearance involves the measurement of 
size, shape, color, presence or absence of odor, taste etc.  
EXPERIMENTAL INVESTIGATION 
 
DEPT OF PHARMACEUTICS, KM COLLEGE OF PHARMACY Page 73 
 
5.5.2 Size & Shape:- 
It can be dimensionally described & controlled. The thickness of a tablet is 
only variables. Tablet thickness was measured by Vernier calliper or by other device. 
Tablet thickness should be controlled within a ± 7.5% variation of standard value.  
 
5.5.3 Unique identification marking:- 
           These marking utilize some form of embossing, engraving or printing. These 
markings include company name or symbol, product code, product name etc.  
5.5.4 Organoleptic properties:- 
Color distribution must be uniform with no mottling. For visual color 
comparison compare the color of sample against standard color.  
5.5.5 Hardness:-. 
Tablet requires a certain amount of strength or hardness and resistance to 
friability to withstand mechanical shakes of handling in manufacture, packaging and 
shipping. Hardness generally measures the tablet crushing strength.  
5.5.6 Friability:- 
Friability of a tablet can be determined in laboratory by Roche friabilator. This 
consists of a plastic chamber that revolves at 25 rpm, dropping the tablets through a 
distance of Six inches in the friabilator, which is then rotated for 100 revolutions. The 
tablets are reweighed. Compressed tablet that lose  weight should be less than 0.1 to 
0.5 % of the tablet weight, which are considered as acceptable.   
                The percentage friability was measured using the formula, 
                                           % F = {1-(W / Wo)} x 100 
 Where, 
         % F = friability in percentage  
                    Wo= Initial weight of tablet 
                    W = Weight of tablets after revolution. 
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5.5.7 Weight variation test:- 
About 20 tablets were weighed individually. Calculated average weight and 
compare with the individual tablet weight. The tablet pass the B.P. test if not more 
than 2 tablets are outside the percentage limit and if no tablet differs by more than 2 
times the percentage limit.   
                     Table no: 12   Weight Variation test as per BP.  
Average weight of tablet Maximum % difference allowed 
80 mg or less 10 
80 mg to 250 mg 7.5 
More than 250 mg 5 
 
% Maximum positive deviation = (WH –A/ A) X 100 
% Minimum negative deviation = (WL - A / A) X 100 
  Where,  WH = Highest weight in mg. 
     WL = Lowest weight in mg,             
                                  A      = Average weight of tablet in mg 
5.6 Stability studies:-84 
Stability is defined as the extent to which a product retains the contents within 
specified limit and throughout its period of storage and use i.e. shelf life, the same 
properties that it possesses at the time of manufacture. These studies were designed to 
increase the rate of chemical or physical degradation of the drug substance or product 
by using exaggerated storage conditions.  
Stability studies are important to prevent the economic repercussions of 
marketing of an unstable product, since subsequent withdrawal and reformulation 
may lead to considerable financial loss. From the point of view of safety to patient, it 
is important that the patient receives a uniform dose of the drug throughout the shelf 
life of the product. 
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The International Conference on Harmonization (ICH) guidelines titled 
“Stability testing of new drug substances and products- Q1A (R2)” describes the 
stability test requirements for drug registration applications in the United States, 
European Union and Japan. 
 As per in vitro release formulation F9 was found to be desirable than other 
formulations. Hence it was chosen for stability studies. The tablets were packed in 
180cc HDPE(high deficiency polyethylene) bottles and kept for 3 months at different 
temperature 25oC / 60%RH, 30oC/ 75%RH, 40oC / 75% RH in a stability chamber 
(Osworld, Mumbai). At the interval of 1 month tablets were withdrawn and evaluated 
for physical properties like thickness, hardness, diameter, friability, weight variation, 
buoyancy studies and content uniformity. In vitro drug   release is also carried out. 
5.7 Kinetic Analysis of InVitro Release Rates of Sustained Release Tablets of 
Glucosamine hydrochloride: 77 
The results of in-vitro release studies obtained for all the formulations were subjected 
to graphical treatments to assess the kinetics of drug release. 
Zero order Equation: 
 The results data was fitted into the Zero order equation. 
 Q = K0t 
 Q = The amount of drug released at time t 
 K0 = Release rate 
First order Equation: 
 The results data was fitted into the first order equation. 
 Log C = Log C0 – k t / 2.303 
 C0 – is the initial concentration of drug 
 K – is the first order constant 
 t - is the time. 
Higuchi Model 
Drug release for matrix devices by diffusion has been described by Higuchi classical 
diffusion equation 
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τ
εε
 
Cst  -(2A D [ ] )
=Q
 
Where,  
 Q = Amount of drug released at time t 
 D = Diffusion coefficient of drug in tablet matrix 
 A = Total amount of drug in unit volume of tablet matrix 
 ε = Porosity of tablet 
            Cs = Solubility of drug in tablet matrix 
 t   =   Time in Min.  
   τ   = Tortusity 
The above equation can be simplified, if one assumes that D, ε,τ , Cs, and A are 
constants. Then equation can be written as  
                                    Q= Kt1/2 
When data is plotted according to the equation i.e. cumulative drug release versus 
square root of time, it yields a straight line, indicating that drug is released by 
diffusion mechanism. The slope is equal to K. 
Peppa’s Model 
In order to understand the mode of release of drug from swellable matrices, the data 
were fitted to the following equation 
                                                  Ktn   
M
Mt
=
σ
 
  where,  
 Mt / Mσ = The fraction of drug released at time t. 
           K = Constant incorporating the structural and geometrical  
                             characteristics of the Drug / Polymer system. 
            n = Diffusion exponent related to mechanism of the release. 
      Above equation can be simplified by applying Log on both sides, we get. 
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 tLogn  K  Log   
M
Mt
+=
σ
Log
 
When the data is plotted as log of drug released versus log time, yield a straight line 
with a slope equal to n and k can be obtained from Y- intercept.  
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7. Results and Discussion 
 
The present study was undertaken to formulate Glucosamine Hydrochloride 
sustained matrix tablets. Sustained release dosage forms deliver the drug at a slow 
release rate over an extended period of time. The drug Glucosamine Hydrochloride is 
formulated as a sustained release matrix tablet due to its high solubility in water and 
maintains required drug concentration in blood. So our aim of patient compliance was 
achieved. 
 
 Different grades of HPMC K100M and HPMC K200M were used as 
swellablepolymers, HPMC (hydroxyl propyl methyl cellulose) was chosen because it 
is widely used as a low density hydrocolloid system upon contact with water, a 
hydrogel layer would be formed to act as a gel boundary for the delivery system and it 
slowly release the drug as per sustained release concept and povidone K90 
combination with HPMC (hyroxy propyl methyl cellulose) also has slow release 
property. 
  
In the present study the 10 formulations were prepared by different polymers 
alone or in combination with diluents, the prepared formulations were evaluated for 
differentphysico chemical characteristics such as thickness, drug content, weight 
variation, hardness, and friability. The release characteristics of the formulation were 
studied ininvitro conditions. 
 
7.1. Preformulation studies:- 
 Based on preformulation data, Hypromellose K200M, Hypromellose K100M, 
Povidone K90 and Ethyl cellulose  was taken as drug release retardants for 
formulation of SR matrix tablets of a highly water soluble drug. 
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Table no: 13Preformulation study data of the pure drug 
S.No  
Parameters 
 
GlucosamineHydrochloride 
1 Angle of repose 22.64 ± 0.002 
2 Bulk density(gm/cm³) 0.66 ± 0.0124 
3 Tapped density(gm/cm³) 0.84 ± 0.0047 
4 Hausner ratio 1.24 ± 0.0081 
5 Carr's index 27.16 ± 0.561 
6 Loss on drying (%) 1.24 ± 0.008 
• Values mentioned are average of 3 determinations 
 
7.2. Characterization of Drug 
 
7.2.1UV- Spectrum Analysis of Drug:-75 
Glucosamine hydrochloride drug solution in distilled water was scanned using UV-
Spectrophotometer between the range 200-400nm shown the maximum absorbance at 
205nm. 
 
7.3. Infrared spectroscopic study:- 
By using FTIR technique Glucosamine hydrochlorideand polymers like 
hydroxy propyl methyl cellulose K100M and K200M were identified. 
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Table no:14Compatibility studies  
Ingredients Observations After 7 days 
Observations 
After 14 days 
Observations 
After 21 days 
Observations 
After 30 days Remarks 
Glucosamine  HCl NCC NCC NCC NCC Compatible 
Glucosamine  HCl 
: IPA NCC NCC NCC NCC Compatible 
Glucosamine  HCl: 
HPC NCC NCC NCC Slight color 
change 
Can be used 
in the very 
small 
quantities 
Glucosamine  HCl: 
Colloidal 
anhydrous silica  
NCC NCC NCC NCC Compatible 
Glucosamine  HCl: 
Stearic acid NCC NCC NCC 
Formation of 
flakes, no 
color change 
Compatible 
Glucosamine  HCl: 
Magnesium 
stearate  
NCC NCC NCC NCC Incompatible 
Glucosamine  HCl: 
PVP (K90) NCC NCC NCC NCC Compatible 
Glucosamine  HCl: 
Ac-di-sol NCC NCC NCC NCC Compatible 
Glucosamine HCl: 
Ethyl cellulose 
NCC NCC 
Slight 
Yellowish-
brown color 
formation 
Yellowish-
brown color 
formation 
Incompatible 
Glucosamine 
HCl:Crospovidone NCC NCC NCC 
yellow color 
developed Incompatible 
Glucosamine  HCl: 
PEG 6000 NCC. NCC NCC NCC Compatible 
Glucosamine HCl: 
HPMC K200M NCC NCC NCC NCC Compatible 
Glucosamine HCl: 
DCP anhydrous  NCC NCC NCC NCC Compatible 
Glucosamine  HCl 
: Microcrystalline 
cellulose  
NCC NCC NCC NCC Compatible. 
 
NOTE: “NCC” – No color change, CC - Color change 
 
 The infrared spectra of pure drug Glucosamine Hydrochloride and mixture of 
polymer and excipients were studied by FTIR spectroscopy. 
 The datas are mentioned in experimental design. The results indicate that there 
was no physical, chemical incompatibility between drug-polymer and other 
excipients. 
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7.4. Evaluation of granules:- 
The prepared granules of the formulations were evaluated for the parameters like bulk 
density, tap density, compressibility index, hausner’s ratio, angle of repose, and loss 
on drying. 
• After granulation, angle of repose was improved. 
• Hausner’s ratio was found to be 1.5 or less than 1.5 
• Carr’s index was found to be in the range of 11-12 
• All the values indicated that the granules have good flow property and hence 
the granulation process has improved the flow property. 
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The tablets were formulated by wet granulation technology using the hydroxy 
propyl methyl cellulose K100M and K200M polymers to show the drug release with 
in the specification. The blended powders of different formulation were evaluated for 
angle of repose, bulk density, tapped density, compressibility index, Hausner’s Ratio 
and drug content uniformity.  
 The result of angle of repose for formulations F5-F10 which indicated the 
good flow properties of the granules. Among them F3, F4, F9, &F10 are found to be 
passable.  
 Compressibility Index indirectly measures the flowability of powder mass for 
all the batches which were  measured and found to be satisfactory for only F3, F4, F9 
andF10 formulations respectively. 
This result is an indication that the transport through the hopper into the feed frame 
and for subsequent die filling could be better for the formulations F3,F4,  F9,F10 than 
F1, F2, F5, F7,&F8 because it is known that the compressibility index  value below 
21% indicates fair flowability of the blend.  
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Depending upon the ingredients of different formulations, the weight of tablet 
was fixed. In each formulation, weight variation was within the I.P limit. Mostly, the 
weight variation should not be more than ±  5%. The hardness of the all 10 
formulations ranged from 21-28 kg / cm2. All the formulations exhibited less than 1% 
friability. 
7.5.Invitro release pattern of sustained matrix tablets: 
 The sustained release tablet was formulated to release the drug up to 20hrs by 
varying the polymers and its concentration. 
 Invitro release study performed in distilled water, paddle type, 50rpm, reveals 
that the release of drug was retarded with the proportional increase of the polymer 
concentration. When the hydrophilic matrix tablet comes in contact with the 
dissolution medium, they take up water and swell, forming a gel layer around the 
matrix.  
 Then the dissolved drug diffuses out of the swollen hydrophilic matrix at a 
rate determined by the amount and viscosity of Hypromellose K200M in the tablet 
formulation. The hydrophilic polymer swells quickly & completely providing a 
stronger gel to prevent the immediate tablet disintegration and controlling the 
diffusion of the drug.  
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Table no: 17DISSOLUTION PROFILE OF F1 BATCH 
 
S.No 
 
Time 
(hours) 
 
Amount of drug 
release(mg) 
 
%Drugrelease 
 
Cumulative % 
drug  release 
1 2 390 26.1 26.14 
2 4 620 41.3 41.35 
3 6 730 48.6 48.69 
4 8 920 61.3 61.43 
5 10 1050 70 70.13 
6 12 1102 73.4 73.55 
7 14 1120 74.6 74.76 
8 16 1230 82 82.16 
9 18 1300 86.6 86.78 
10 20 1362 90.8 90.99 
 
 
Figno: 7Dissolution profile of F1 batch 
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7. CONCLUSION 
 Glucosamine is an amino monosaccharide which is used for the treatment of 
osteoarthritis. Glucosamine is an essential component of mucopolysaccharides and 
chitin. Mucopolysaccharides (glycosaminoglycons) are large complexes of negatively 
charged carbohydrate chains that are incorporated into mucous secretions, connective 
tissue, skin, tendons, ligaments and cartilage.  
Sustained release matrix tablet of Glucosamine Hydrochloride could be 
successfully formulated by wet granulation method with active ingredient in both 
intra and extra-granular part by using different viscosity grades of Hydroxy Propyl 
Methyl Cellulose, Avicel PH102 used as a diluent, povidone K90F used as binder, 
stearic acid as a lubricant. The optimized tablet formulation had showed 99.84% of 
drug release in 20 h. Therefore the optimized formulation containing HPMC K200M 
with Avicel PH102 sustained the drug release for a period of 20 h and remains 
throughout the studies. Among the different grades of HPMC, HPMC 200,000 cps or 
HPMC K200M showed the maximum retardation in drug release.  
      The invitro dissolution profile of drug release from the tablets followed 
zero order kinetics. From the higuchi plot of dissolution profile, we found that the 
drug was released by diffusion mechanism and from peppa’s plot we concluded that 
the release mechanism was found to be non Fickian release. The optimized 
formulation undergoes stability study at 25◦C / 60%RH, 30◦C / 65%RH, 40◦C 
/75%RH. There was no change in physical characteristics and dissolution study.  
Finally, it was concluded that Sustained release matrix tablet of Glucosamine 
Hydrochloride can be prepared by using higher viscosity grades of HPMC as HPMC 
K200M had sustained the release of the drug for a prolonged time.  
It is a promising approach as it can lead to release the required quantity of 
drug to the body, which results in minimizing the major side effect as tachycardia by 
minimizing the drug concentration in blood and also the entire dose is released at the 
target site and ultimately lead to better patient therapy. 
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